Spot on Biotechnology Business 2016-2017 by BIO.NRW Cluster Biotechnology NRW

ny a p Co m o r y ct D i re

Spot on Biotechnology Business 2016/2017

From Mind to Market: Biotechnology Company Directory 2016/2017 North Rhine-Westphalia

BIO.NRW

Editorial Dear Reader, North Rhine-Westphalia is the home of biotechnology. From the establishment of the Institute of Biotechnology at the Jülich Research Centre in the late 1970s to this day, the sector has been developing continuously. Our state has become a true biotech hub. Over the past nine years, the number of biotechnology firms in NRW has all but doubled - and this is looking only at those businesses that meet the OECD’s definition of ‘dedicated biotech firms’. There are more - and mostly bigger - companies where biotech products and processes account for a significant portion of the turnover. This creates jobs and helps retain the high quality of research and development. Of course, our success did not spring from nowhere. In North Rhine-Westphalia, we have, on the one hand, all the right conditions, including an outstanding research landscape. On the other hand, biotechnology firms in our state are embedded in a robust environment of chemical and pharmaceutical global players. On top of that, the State Government is busily creating an

is intended to be a biotechnology almanac designed to help you make new contacts and find partners for cooperation. Why not come to Cologne and use the opportunity to meet prospective partners face to face at the BIO-Europe 2016 event from 7 to 9 November. Visit the stand of the ‘BIO.NRW State Cluster’ at Europe’s premier business-to-business matchmaking conference for the life-science sector. Let me now wish you successful networking and many new partners for cooperation.

innovation-friendly climate and infrastructure which will assist the faster translation of knowledge and expertise into marketable products and techniques. This is done with a view to keep the regional biotech sector at the leading edge of technology and market savvy. One of the keys to success is the cooperation across disciplinary lines. This booklet

Svenja Schulze

North Rhine-Westphalia Minister for Innovation, Science and Research

BIO.NRW

Greeting Dear Reader, Welcome to one of the world’s biggest biotechnology hotspots. The area of North Rhine-Westphalia (NRW) is one of Europe’s fastest growing biotech landscapes. With 95 dedicated biotechnology companies and 19 other life science related companies this is one of Germany’s densest biotech-networks, complemented with an excellent academic environment. Strikingly, also numerous global players are among these companies. Emphasizing the importance of NRW’s biotech landscape, the biggest industrial deal of the year, the biggest deal a German company ever made, is currently being tied up here. The Bayer AG is buying the U.S. seed giant Monsanto for $66 billion, an event with global influence. The fusion of both companies makes Bayer the world’s largest supplier of agricultural chemistry. Obviously, biotechnology is tightly linked to this branch. The rising influence of biotechnology on our daily life reveals that it is one of the key technologies for the future development of our society and industry. Hence, it is not surprising that biotechnology was and is still shaping NRWs industrial landscape. 10 Years ago a key communiqué, the Cologne paper, was published, describing the societal challenges of a sustainable development by bioeconomy. The aim of bioeconomy is a circular economy, reducing pollution and direct processing of all produced products incl. potentially unwanted waste products. More than 40 countries are by now actively promoting bioeconomy. Main ideas of a circular economy are already accomplished, though there is still a long way to go. Biomass is not used in an optimal way, yet. Although, biomass supply chain management became a key feature of

mostly all modern industries, a big amount is still wasted, exemplary as not recyclable fuel material for energy production. More sophisticated technologies as well as more measureable parameters on the impact of bioeconomy on society and industry will become key elements for continuous success of bioeconomy. To obtain more measurable data of the development of the biotech industry all German biotech clusters/regions agreed this year for the very first time on a consistent company/business survey conducted by BIO Deutschland e.V. These data will provide deeper insides about the development of Biotech regions all over Germany. Making a long story short, the first report indicates a big success of the biotech companies in NRW, exemplary with an overall increase in turnover, money spend into Research & Development and increasing numbers of employees. A more illustrated analysis about the key developmental facts of this region is provided in the 8th annual compen-

dium of NRW’s biotech business landscape “Spot on Biotech Business”. In March 2016 BIO.NRW hosted in partnership with EIT Health the 5th Business Angel Congress in Dusseldorf. Here, more than 100 policymakers, business angel investors and government representatives came together, stimulating the entrepreneurship and innovation for SMEs. BIO.NRW also became host of the BioEurope, Europe’s biggest partnering event in life sciences, taking place in Cologne in November 2016, adequately to the spatial origin and 10th birthday of the Cologne paper on bioeconomy. On the occasion of this event also the current issue of the “Spot on Biotech Business” is released. I invite everybody to take advantage of our offerings and to engage with our state’s extensive and excellent biotech community.

Dr. Bernward Garthoff Cluster BIO.NRW

Representative for Biotechnology of the German State of North Rhine-Westphalia

BIO.NRW

© 2016/17, BIO.NRW “Spot on Biotechnology Business” www.bio.nrw.de Print: Druckstudio Gruppe, Düsseldorf Design and Layout: it’s FR!TZ Picture Source: p. 4 © SergiyN – fotolia.com p. 6 © it’s FR!TZ p. 10 © Chepko Danil – istockphoto.com p. 12 © Wavebreakmedia – istockphoto.com p. 14 © Li Ding – istockphoto.com p. 16 © anyaivanova – istockphoto.com p. 18 © Songsak Paname – istockphoto.com p. 20 © Shironosov – istockphoto.com p. 22 © anyaivanova – istockphoto.com p. 28 © Alex Raths – istockphoto.com p. 37 © BIO.NRW; Institute of Biochemistry, University of Cologne p. 38 © Shironosov – istockphoto.com p. 52 © miszaqq – istockphoto.com p. 58 © Toa55 – istockphoto.com p. 61 © it’s FR!TZ p. 62 © HYWARDS – istockphoto.com p. 64 © luchschen – istockphoto.com p. 74 © G. Mönks – fotolia.com

BIO.NRW

Content

Editorial…

………………………………………………………………………………

Company Directory 2015/2016 NRW

Greeting… ……………………………………………………………………………… 7

Non-specific Services… …………………………………………………… 28

Spot on Biotechnology Business… ………………………………… 11

Health and Medicine (including Animal Health)… …… 38

Biotech Landscape……………………………………………………………… 11

Industrial Biotechnology… ……………………………………………… 52

Stimuli for Start-Up‘s…

……………………………………………………… 11

Agrobiotechnology… ………………………………………………………… 58

Academic Biotech Research … ……………………………………… 13

Bioinformatics… ………………………………………………………………… 62

Biotech Business… …………………………………………………………… 17

Other Biotechnologically Active Companies……………… 64

Competence Clusters… …………………………………………………… 21

BIO.NRW Cluster Biotechnology North Rhine-Westphalia… ……………………………………………… 70

Industrial Biotechnology – CLIB2021 ……………………………… 21 Pharmaceutical Biotechnology – BIO.NRW.red … …… 23 From Mind to Market …

……………………………………………………

Biotechnology Map of North Rhine-Westphalia Life Science Technology Parks and Incubators �� 24 Biotechnology Map of North Rhine-Westphalia Dedicated and other biotechnologically active companies �� 26

Glossary �� 72 OECD Definition… ……………………………………………………………… 72 Organisation for Economic Co-operation and Development (OECD)… …………………………………………………… 72 Biotechnology company…

………………………………………………

Dedicated biotechnology companies … ……………………… 72 Other biotechnologically active companies… …………… 72 Business Areas of Activity… …………………………………………… 72 Contact BIO.NRW……………………………………………………………… 72 Sources, Literature, Links…

……………………………………………

BIO.NRW

Spot on Biotechnology Business

Biotech Landscape North Rhine-Westphalia (NRW) is at the heart of Europe. 150 million people – a third of the population of the European Union – live within a day’s drive of Düsseldorf, the state capital. 30 percent (i.e. EUR 189.8 billion in 2014) of the direct foreign investment that flows into Germany ends up in North Rhine-Westphalia, where some 18.000 international companies control their German and European operations from. NRW also is the number one trading state among Germany’s 16 federal states.1 Summing up the in- and export of NRW the trading volume is EUR 388.8 billion. With around EUR 646 billion, NRW generates 21.3 % of the German GDP, putting it clearly at the top of all German federal states. It accounts for 4.4 percent of the European GDP (EU-28), making it one of the most important economic regions in Europe. Comparing NRW in an international ranking, it is ahead of several European countries such as Switzerland, Sweden, Poland, Turkey and Belgium.2 With 17.9 million inhabitants of which 9.9 million live in the Rhine-Ruhr area, that lists among the top 35 metropolitan areas in the world – NRW is by far the most populous German state. Consequently, the state boasts the highest level of infrastructure within Germany including the country’s densest railway network and seven international airports. Handling more than 129 million tons of goods per year, Duisburg is the world’s largest inland port. With over 100 annual international trade fairs NRW has the largest trade fair venue of the world. Colognes “Koelnmesse” is the No.1 venue for more than 25 different industries. Traditionally, North Rhine-Westphalia has been Germany’s most important location for

the pharmaceutical and chemical industry. Today the state has also developed into a life sciences hotspot: A good reason for many top-level biotechnology companies and research institutes to have their headquarters here. Numerous successful start-up and spin-off companies are flourishing in NRW alongside a strong chemical and pharmaceutical industry that includes many well-known household names like Bayer, Evonik, Henkel, Grünenthal, Johnson & Johnson or UCB. This business excellence is endorsed by a dense network of outstanding academic institutions, which focus on biotechnology within a broad life sciences landscape. In addition, there is an equally rich and robust funding environment to support and promote the industry, including venture capital providers and business development organizations. Biotechnology in NRW represents an active, multi-centric network, which is setting the

95 dedicated biotechnology companies

19 other biotechnologically active companies

~329 other life science related companies

Fig. 1: Life Science Company Landscape in North Rhine-Westphalia

pace for the powerful pulse of the state’s life science business. Meanwhile biotechnology is a maturing industry that expands rapidly. Its innovative technologies are applied to major industry branches serving health/ medicine, chemistry, food and environment. North Rhine-Westphalia has been developing its biotechnology hotspot since 1995. More than 20 years into the program, over 400 life science related companies are located here – among them 114 biotechnology enterprises including several global players (Figure 1). Major business areas covered are industrial, nano- and pharmaceutical biotechnology, and there is a focus on enabling technologies and supporting services as well. Combining the strong technical expertise evolving from these areas has been the key driver for NRW as the state is pioneering the field of bioeconomy in Germany.

Stimuli for Start-Up‘s Many of today’s successful young biotech companies started as university spin-offs. They took advantage of life science incubators and technology centers, whose existence can be pivotal for a start-up company. As catalysts for regional infrastructure and economic development, there are approximately 60 such centers and incubators in the immediate vicinity of universities and basic research institutions in NRW. They support technology transfer all the way from mind to market. At the time of the editorial deadline of this brochure, a total of 158 biotech and life science related companies were incubated by 26 of these technology centers.3 You will find the respective locations of the centers and the number of biotech companies each 11

BIO.NRW

Fig. 2: Biotechnology is a strongly linked industry

IDEA Branch

BIOTECHNOLOGY

of them hosts on the map on page 24. The services these start-up centers provide include renting affordable laboratory and office space, mediating business contacts, consulting on funding opportunities, and advising on either founding or relocating a firm. Businessplan competitions are offered as an additional chance for support. One technology park that deserves to find special mention here is BioCampus Cologne, one of the largest of its type in Germany. It houses more than 23,000 square meters of office and laboratory space, including state of the art S1- and S2 labs, and industrial production facilities on a site totaling more than 25 hectares. Company founders, young entrepreneurs and scientists all profit from NRW’s highly-networked biotechnology scene.

Academic Biotech Research

Product/Service

Agriculture

(functionalized) Foods / Fertilizer / Crops / Plant Protection

Basic Research

Basic/fundamental / Pre-requisite for applied reserach and development

(Biomedical) - IT

Laboratory Information Systems / Digital Healthcare / Biological Computing / Databases

Chemical Industry

Proteins / Peptides / Chemicals through Biotech Processes (Enzymes, MO) / Molecular Electronics

Energy

Raw Materials/ Fuels

Facilities / Infrastructure

Transport ⁄ Laboratory supply / Materials

Healthcare / Pharma

Drug Delivery / (Companion) Diagnostics / Medical Devices / Therapeutics

analytics/microsystems, bioinformatics and process engineering are all on offer. For over a decade, NRW has been the leading German region in stem cell research and development with Münster, Bonn and Cologne as hotspots. In the field of plant

genetics, the Max-Planck-Institute for Plant Breeding Research, Cologne deserves to be called the “cradle of plant biotechnology” in Germany as the first plant transformation technologies were developed here. It is now tightly interacting with the newly founded

Fig. 3: Growth of life science companies compared to dedicated biotech companies accumulated percetage of companies

North Rhine-Westphalia is offering Germany’s most comprehensive network of academic institutions consisting of internationally renowned Universities and Universities of Applied Sciences (71; 25 with life science activity), Max Planck Institutes (13; 6 with life science activity), Fraunhofer Institutes (14; 5 with life science activity), Helmholtz Institutes (3; 3 with life science activity) and Leibniz Institutes (11; 7 with life science activity). One quarter of all German students are taking advantage of this excellent environment for science and education and are pursuing their studies in NRW, remarkably one third of all STEM fields (Science, Technology, Engineering and Mathematics) students are studying in NRW. University centers can be found in Aachen, Bonn, Cologne, Düsseldorf, Münster, Bochum, Essen, Dortmund, Bielefeld, and other cities in the state. In the area of biotechnology, specializations in cell biology, (bio-) medicine, biochemistry, genomics, proteomics, metabolomics, molecular biology, systems and synthetic biology,

MARKET

100 80 60 40 20 0 1995

1997

1999

2001

2003

2005

Life Science companies

2007

2009

2011

2013

2015

Biotech companies 13

BIO.NRW

Table 1: Key Figures for the Biotechnology Industry of North Rhine-Westphalia 95 dedicated biotechnology companies in 2015 (89 in 2014, 87 in 2013, 84 in 2012 ) 2012

2013

2014

2015

Number of employees*

3,758 (n=67)

3,680 (n=67)

3,758 (n=68 )

3,983 (n=75)

4,387

Turnover*

EUR 1.34 bn (n=32)

EUR 1.27 bn (n=29)

EUR 1.32 bn (n=25)

EUR 1.51 bn (n=30)

EUR 1.66 bn

R&D expenditure*

EUR 190 m (n=30)

EUR 214 m (n=29)

EUR 241 m (n=22)

EUR 258 m (n=30)

EUR 337 m based on survey Biodeutschland and imputation statistics

based on survey BioDeutschland

based on survey BIOCOM * Data based on survey data as indicated; n means number of companies giving indication

Cluster of Excellence on Plant Science (CEPLAS) that was founded in 2012 - an EUR 32 million collaboration of several universities and research institutes. Recent examples from Cologne emphasize the very dynamic development of NRW as a research location: in May 2013 the all new research facilities of CECAD (Cluster of Excellence – Cellular Stress Responses in Aging-Associated Diseases) have been opened – an investment of EUR 85 million. In October 2013 the Max-Planck Society

Fig. 4: Size of Dedicated Biotechnology Companies (Number of Employees) 7%

Business Year

NRW / %*

Germany

2007

53 / 10.7

496

2008

61 / 12.2

501

2009

68 / 12.8

531

2010

71 / 13.2

538

2011

77 / 14.0

552

2012

84 / 14.9

565

2013

87 / 15.3

570

2014

89 / 15.4

579

2015

95 / 16.1

590

* % of Germany total

10%

40% 43%

below 10 10-49 more than 250

Table 2: Number of dedicated biotech companies

50-250

opened the new facility of the Max-Planck Institute (MPI) for Biology of Ageing in immediate vicinity to the new CECAD building on the university campus. They offer cutting edge infrastructure and technology, incl. laboratory and office space for together more than 700 international scientists, staff and students. Directly next to the MPI and CECAD the Cancer Center Cologne (CIO) is located. To obtain a fast pipeline from basic research to final therapeutics the CIO is currently being expanded for EUR 78 million.

Here, newest research progress is directly implemented into individual therapies for the patient’s well-being. Additionally several world leading neuroscience institutes are located in close proximity. Alone in 2013 more than EUR 193 million was invested into the neuroscience research facilities of the DZNE (German Center for Neurodegenerative Diseases) and the de-

Fig. 5: Areas of activity

25%

27% 5%

11% 14%

5% 8% Therapeutica Diagnostica Drug Delivery Industrial biotechnology Bioinformatics Agrobiotechnology Non-specific services 15

BIO.NRW

partment of the university hospital Bonn. Along with the respective institutes of the Universities of Cologne and Bonn as well as their University Hospitals plus the DZNE in Bonn, Cologne has been developed into a world-wide unique competence center for ageing research. About one hour east of Cologne, Europe’s most innovative technology campus is currently taking shape: covering 800.000 square meters, “Campus Melaten” of the RWTH Aachen University will house up to 11 technology clusters, among them the “cluster biomedical technology” and take up investments of EUR 1 billion. Cooperation of academia and industry are creating synergy effects, e.g. recently the Forschungszentrum Jülich initiated a cooperation with Bayer on plant root and shoot phenotyping. BIO.NRW offers detailed information about the academic life science landscape in NRW in its compendium “Spot on Biotechnology Science. This brochure is composed in a similar manner like „Spot on Biotechnology Business“ and presents a total of 227 profiles of research institutes, centers and facilities in NRW. Its second issue has been released simultaneously with this brochure in November 2016.

Biotech Business Biotechnology became one of the most dynamic business sectors over the last decades. Having such a complex industry it is hard to find a simple value chain or to separate it from other, more “static”, industries. Biotechnology routinely uses other technologies, e.g. Nanotechnology and Engineering, to improve products. However, all colors of biotechnology (green, red, white and blue) are linked to diverse other branches like the chemical industry (Figure 2). Looking on single services and products makes it obvious that looking on dedicated biotechnology companies only reveals a minority of the impact biotechnology has on the entire industry. A good example

for this is the energy branch with respect to biofuel. The revenue of biofuel was alone in the U.S. $9.7 billion in 2012.4 In terms of the definition of a dedicated biotech company, the production of biofuel does not belong to the biotech industry, even though mostly all production process steps are based on biotech techniques. Obviously, more distinct definitions may help to analyze the impact of biotechnology on the overall industry and society. To have a more uniform definition of biotech companies for Germany BIO Deutschland e.V., the branch association of the German biotech industry and organizations, decided to introduce a new statistical analysis, carried out by

BIO Deutschland itself. This statistical analysis will allow a more sophisticated analysis of the biotechnology landscape in Germany. It was carried out this year for the very first time and will be continued over the next decades, facilitating a more comprehensive comparison for all individual German states over the next years. The framework of the analysis is set by the OECD definition of a dedicated biotech company and biotech associated companies (see page 72). Based on this definition, 95 dedicated biotech companies were operating in NRW in 2015. Their activities were complemented by 19 other companies with a biotechnological commitment, mostly global players in the field of pharmaceuticals,

Fig. 6: Drug Development Pipeline by Indication Indication

Number of Products

Neoplasms / cancer / oncology

Infectious and parasitic diseases

Diseases of the nervous system

Symptoms, signs abnormal clinical and laboratory findings, not elsewhere classified Skin and subcutaneous tissue

6 4

Musculoskeletal system and connective tissue

Diseases of the blood and blood-forming organs; immune disorders

Respiratory

Mental and behavioural disorders

Other

Cardiovascular

Digestive system

Total

72 17

BIO.NRW

chemicals or seed production. Since these companies are active in many diverse areas, their biotech related business figures cannot be calculated exactly and are not included in the following statistics. The real economic impact of biotechnology in NRW is therefore higher than these statistics reveal. These companies are at the innovative core of biotechnological research and development. In contrast to the business figures of the dedicated biotech companies – as an example – the 2015 sales of Bayer AG and Evonik Industries AG alone, both headquartered in NRW, are EUR 46.3 billion and EUR 13.5 billion, respectively. Even though only a part of their turnover can be assigned to NRW sites and not all products are generated involving biotech processes, the key business sectors of both companies are based on biotechnology. These two examples clearly demonstrate the enormous impact biotechnology has on the overall industry in NRW and Germany. According to the 2009 OECD Biotechnological Statistics report (which – except for limited “indicator” updates - still is the latest published detailed study in the field by the OECD), North Rhine-Westphalia is Europe’s most innovative biotechnology region: It generates more biotech PCT patent applications than any other European region.5 The development of biotech innovations from NRW has been constantly increasing: 4,121 biotech patents have been filed in total between 1996 and 2010 by NRW biotech companies and research facilities of which 4,118 have been published.6 The business figures of the 95 NRW dedicated biotech companies are set into comparison with the 590 German dedicated companies and the 495 German companies without the NRW contribution, respectively. In NRW about 4,000 people (of about 18,000 nationwide) – more than in any other German federal state – were employed by dedicated biotech companies in 2015 and generated a turnover of approximately EUR 1.51 billion

(Table 1). According to the national company survey by Ernest & Young the NRW dedicated biotechnology companies generated about 44.4% of the German biotech annual turnover (EUR 3.4 billion expected) in this sector which is a slight increase compared to 2014.7 Thus, the biotech industry in NRW is - to a large extend - responsible for the economic impact of the German biotech business as a whole. EUR 258 million – a significant annual increase by 7.1% compared to 2014 and 20.6% compared to 2013 (EUR 241 and EUR 214 million) – was reinvested into R&D projects.8 The development of this key business figure underlines that the investments by the dedicated biotech companies in NRW are persistent and will advance the future market position of NRW biotech. Together, NRW biotech firms are placing the highest investments for R&D of innovative products – nationwide. Overall, the proportional expenditure for R&D of 17.1% of the annual turnover is more than 5 times higher than the mean of all other businesses in Germany (average of 2.9%).9 The figures reflect that biotechnology as a business sector is in the process of maturation: 46 % of all life science companies are older than 20 years and were founded before 1997 whereat only 24 % of all biotech companies in NRW already existed in 1996. Looking at the balance of still existing

and newly founded companies in average 10.1 successful life science companies were founded annularly (within an annual growth rate of 3.0 %). At the same time 4.6 successful biotech companies were established (growth of 4.2 %). Hence, 45.7 % of all new founded life science companies are in fact biotech companies (in 1996 17.6% of all life science companies were biotech companies, 27.4% in 2016) (Figure 3). However, important factors that reduce the average company age in the industry are new foundations and acquisitions of successful ventures by global players as well as re-orientations of companies. The employee structure remains almost unchanged: about 83 percent of the biotechnology companies in NRW employ fewer than 50 people and 93 percent of the companies have less than 100 employees (Figure 4). After financing rounds of EUR 58.9 million in 2014, mostly due to AYOXXA Biosystems GmbH (EUR 20.3 million) and Protagen AG (EUR 10 million), financing rounds of biotech companies dropped to EUR 24.7 million in 2015, mostly contributed by Neuway Pharma GmbH with EUR 5.9 million. With six new dedicated and three new other biotech-active companies in NRW in 2015 the state’s biotech scene continues to be one that’s growing at fastest pace in Germany. Over the past two years the state even counts

Fig. 7: Drug Development Pipeline by Phase On the Market 6 Phase III 3 Phase II 2 Phase I 8

n/a 4

Discovery 7

Lead optimization 1

Preclinical 47

BIO.NRW

12 new companies leading to 95 dedicated and 19 and other biotech active companies today (Table 2). In 2015 27 percent (32 in 2014) of the biotech companies in North RhineWestphalia were active in multiple branches (Figure 5). These biotechnology companies with “nonspecific business activities” include service providers and suppliers for the industry. Germany’s two largest biotech companies with the highest numbers of employees in Germany 10, QIAGEN GmbH and Miltenyi Biotec GmbH used to be listed here. As Qiagen has developed into the field of medical applications, meanwhile the company is accounted as a dedicated biotech company in the „health-medicine“sector in this survey. QIAGEN began as a spin-off from the University of Düsseldorf in 1984. Today, the company employs more than 4,600 experts at 37 sites worldwide, and has become the leading provider of sample technology and a top player in molecular diagnostics especially in cancer detection and prevention. Through a number of strategic moves QIAGEN today is one of the leading companies in biomarker discovery and development (i.e. companion diagnostics), which is the basis for the company’s redirection to the health business. Based on the invention of a magnetic cell separation technology, Miltenyi Biotec was founded 1989 in Bergisch Gladbach near Cologne. Since then, the company has expanded to 1,600 employees worldwide who produce and market over 11,000 products for the global biomedical research community. It is remarkable that this success has been solely achieved by generic growth. The majority of dedicated NRW biotech companies (46%; 44.9% in 2014) are active in the field of health and medicine developing new drugs or diagnostics within the pharmaceutical sector. At the time of the editorial deadline of this brochure the dedicated biotech companies in the field of health and medicine had developed a drug pipeline of in total 72 products and product candidates, remaining mostly

constant over the last years. The detailed distribution by indication lists as clear top one category “neoplasms/cancer/oncology”, it increased by 15 compared (2015 - 17 products) to 32 products in pipeline in 2016 (Figure 6). This is followed by “infectious and parasitic diseases” that dropped from 18 (2015) to 10 products in pipeline (2016). “Diseases of the nervous system” (7) remained mostly constant compared to 2015 with 9, and “symptoms, signs and abnormal clinical and laboratory findings” (6) increased by 5 (1 product in 2015). The pipeline includes 13 therapeutics (18.1%) in the clinical phases I to III (17 in 2015, Figure 7).11 The majority of products (47 – 65.3%) are preclinical drug candidates. The overall number of products in development pipeline slightly dropped compared to 2015 with 78 products (-6.7%). With 14 percent (16.9% in 2014) – compared to 10.1 percent of companies in this sector across Germany – industrial biotechnology remains a characteristic strength of NRW.12 The underlying classification refers to companies that develop enzymes, biomaterials or bioprocesses, which can be applied to facilitate or enable large-scale production in the chemical industry. The NRW-based companies Henkel and Evonik have been pioneering industrial biotechnology worldwide and are still its pacesetters.

Competence Clusters Besides the large number of biotech companies, which have specialized in enabling technologies, two main fields of activity characterize the biotechnology landscape in North Rhine-Westphalia: Industrial Biotechnology and Pharmaceutical Biotechnology.

Industrial Biotechnology – CLIB2021 CLIB2021 (Cluster Industrial Biotechnology 2021) is an international open innovation cluster of large companies, SMEs, academic

institutes and universities as well as other stakeholders active in biotechnology and bioeconomy as a whole. The cluster comprises over 100 members with a share of about 25 % international members. The overall goal of CLIB2021 is to network stakeholders along and across value chains and to identify new opportunities for innovation, projects, and business. The cluster mainly focuses on industrial biotechnology to provide solutions for the chemical industry: raw materials, biocatalysts, processes, products and technologies that result in monomers, fine chemicals or in their functionalization. Pertinent project areas are identified by the CLIB2021 team in conjunction with members in an iterative process. CLIB2021 is a non-profit association, with its members shaping the cluster’s interests and activities. The cluster coordinates several associated programmes which cover different aspects of bioeconomy, and invites members to become involved, bring in their own ideas and to generate a real benefit for their companies or institutions. To this end, CLIB2021 organizes a number of events throughout the year: the annual CLIB international conference (CIC), forum events, topic-specific workshops, dedicated small partnering meetings and visits to partners, sites or meetings in Germany and abroad. In NRW, CLIB2021 is coordinating the regional innovation network (RIN) “Stoffströme”, which seeks to improve exploitation of biomass, wastes and side streams in the region. This action is funded by NRWs Ministry of Innovation, Science and Research (MIWF). Another NRW-based project is dedicated to improve identification and production of high performance ingredients (HiPerIn) for markets like adhesives, cosmetics or food and feed. Together with partners in Germany, Flanders and the Netherlands, CLIB 2021 is currently establishing the BioInnovation Growth mega-Cluster (BIG-C). This is supported by the German Federal Ministry of Education and Research (BMBF) through a 21

BIO.NRW

5-year, 4 million Euro project, that started in 2016. It deals with the development of cross-border novel value chains based on lignocellulose and the C1 gases CO and CO2 to produce chemicals. Moreover, it focuses on cross-border education concepts conveying required competences for the establishment of a circular economy.

Pharmaceutical Biotechnology – BIO.NRW.red In the last decades, major milestones in medicine and healthcare have been achieved through pharmaceutical (“red”) biotechnology, namely in the development of drugs, vaccines and diagnostics. In 2015, half of all 590 dedicated German biotech companies (51%) belong to the red biotechnology field. Twothird of this sector belong to the therapeutics segment, focused on drug development.12 With a closer look to the medical biotechnology area, respectively to biopharmaceuticals it becomes obvious that 2015 was another strong year. 15 out of 50 newly approved drugs were biopharmaceuticals, more than ever before (30%). 13 Their sales in Germany increased by 9.7% in 2015 relative to 2014 and reached a volume of about EUR 8.2 billion, which corresponds to 22.9% of the total pharmaceutical market in 2015. Indications with a high medical need are still immunological diseases and Oncology and the increase in growth was most significant in these segments (Immunology by 11% and Oncology by 12%). It is interesting to note that more than two-third (71%) of the biopharmaceutical sales is generated by indications in immunology, oncology and metabolism.13 For more than a century, NRW has been the heartland of Germany’s pharmaceutical industry and has an exceptional standard in biotechnological and medical education. This advantage, combined with the enormous market potential of biopharmaceuticals, gave reason for BIO.NRW’s strategic initiative in

the field of red biotechnology called BIO. NRW.red. Its starting point was the competition “Bio.NRW” in 2009, a call for projects announced by NRW’s Ministry of Innovation, Science and Research (MIWF) to support the formation of consortia between academia and biotech companies. The focal areas of the successful projects were: development of drugs (biologicals and small molecules), generation of new methods in diagnostics, establishment of biomarkers and introduction of new biopharmaceutical technology platforms – especially based on cell cultures technology. Since 2009 the MIWF announced several further calls for proposals in the field of red biotechnology like “PerMed.NRW” (by the end of 2010), focused on personalised medicine and “Translational Stem Cell Research” (finished in June 2014). These activities continue to effectively boost the BIO.NRW. red initiative. By the end of 2014 a new series of competitions were published by NRW’s state government, focussing on translational research in eight so-called “main markets” (NRW Leitmarktwettbewerbe), adopting a “two-rounds funding model”. The results of the first round in the main market “Life Sciences” were published in December 2015. Ten innovative research projects will be funded by 20 Million euros.14 The announcement of the results for the second round (ended in June 2016) will be expected in the end of October 2016. Members of the new successful consortia will expand the sustainable BIO.NRW.red network that connects major contributors to medicine, healthcare, the pharmaceutical industry and red biotechnology in the state.

OECD guidelines (page 72). For convenience, the companies are grouped in five areas according to their main business: Non-specific Services Health and Medicine (including Animal Health) Industrial Biotechnology Agri/Agrobiotechnology Bioinformatics Other biotechnologically companies For a more comprehensive directory that includes all life science and life science related companies in NRW, please visit our company database at www.bio.nrw.de/en/company_database. BIO.NRW invites you to discover North Rhine-Westphalia‘s biotechnology community!

From Mind to Market This chapter provides an overview of 81 of the dedicated and 12 of the other biotechnological-active companies from North Rhine-Westphalia as classified following the 23

BIO.NRW

Biotechnology Map of North Rhine-Westphalia Life Science Technology Parks and Incubators

The Netherlands Q

Gronau

Weser

4 8

Münster

Ascheberg

3 ine

Rh Lippe

Q Bönen Dortmund 10

QQ Nettetal Kempen

Düsseldorf

Essen 6 2 Q Q 1 Q 1 Q Bochum 27 Essen 5 3 Q Witten 1 Q Wuppertal

14 10 7

Belgium 24

5 22 Q Köln 3 Q

Bergisch-Gladbach

Troisdorf e

Aachen

Witten

in Rh

Q Q

Q Hilden QQ Monheim Langenfeld Q

BaesweilerQ 2 Jülich Herzogenrath 6 Q

Ruhr

Bonn Rheinbach Q 3

Germany

3 Em

Bielefeld

Rheda-Wiedenbrueck

BIO.NRW

Name

City

Companies*

Homepage

Zentrum für Bio-Medizintechnik (ZBMT)

Aachen

www.agit.de

INCA Technologiezentrum GmbH

Ascheberg

www.inca-technologiezentrum.de

its-Internationales Technologie- und Service-Center Baesweiler

Baesweiler

www.its-center.de

Technologiepark Bergisch-Gladbach

BergischGladbach

www.tbg.de

Technologiezentrum Bielefeld

Bielefeld

www.technologiezentrum-bielefeld.de

BMZ - BioMedizinZentrum Bochum

Bochum

www.bmz-bochum.de

TZR - Technologiezentrum Ruhr

Bochum

www.chip-tzr.de

Bio-Security

Bönen

www.bio-security.de

B1st Software-Factory Dortmund

Dortmund

BMZ - BioMedizinZentrum Dortmund

Dortmund

Zentrum für Mikro- und Nanotechnologie

Dortmund

www.mst-factory.de

LSC - Life Science Center Düsseldorf

Düsseldorf

www.lsc-dus.de

ETEC - Essener Technologie- und Entwicklungs-Centrum GmbH

Essen

www.etec.de

TPH - Technologie Park Herzogenrath

Herzogenrath

www.tph.de

Technologiezentrum Jülich

Jülich

www.tz-juelich.de

TZN - Technologie- und Gründerzentrum Niederrhein GmbH

Kempen

wwwtzniederrhein.de

BioCampus Cologne Grundbesitz GmbH & Co. KG

Köln

www.biocampuscologne.de

RTZ - Rechtsrheinisches Technologie- und Gründerzentrum Köln

Köln

www.rtz.de

TechnologiePark Köln

Köln

www.tpk.de

20 Creative Campus Monheim

Monheim

www.cc-monheim.de

Münster

www.technologiefoerderungmuenster.de

22 CeNTech - Center for Nanotechnology

Münster

www.centech.de

23 Gründer- und Technologiezentrum Rheinbach

Rheinbach

www.wfeg-rheinbach.de

24 Forschungs- und Entwicklungs-Zentrum Witten GmbH

Witten

www.fez.de

Witten

www.zbz-witten.de

Wuppertal

www.w-tec.de

Technologieförderung Münster GmbH

ZBZ - Zahnmedizinisch Biowissenschaftliches Forschungs- und Entwicklungszentrum Witten GmbH

26 Technologiezentrum Wuppertal W-tec GmbH Total: 26

www.b-1st.de www.bmz-do.de

158

* Life Science Companies

BIO.NRW

Biotechnology Map of North Rhine-Westphalia Dedicated and other biotechnologically active companies Q

Q Westerkappeln Osnabrück

The Netherlands Q

Gronau

Q Q

Münster Q

Q ine

Bergkamen Q

Q Bottrop Q Marl Gelsenkirchen

Duisburg

Nettetal Düsseldorf Q Neuss Q Mönchengladbach Q Monheim

Wuppertal

Erkrath

Rheda-Wiedenbrück

Bönen

Dortmund Bochum Q Witten Essen Q

Bielefeld Q Leopoldshöhe

Lippe

Moers Q Q

Ascheberg

Weser

Bad Salzuflen

Ruhr

Q Hilden Q Langenfeld Q Leverkusen Q Bergisch Gladbach

Baesweiler Q Köln Q Q Jülich Herzogenrath Niederkassel Q Q Würselen Q Aachen Q Mechernich Q Bonn Q

Troisdorf St. Augustin

ine Rh

Belgium

Q Q

Germany

BIO.NRW

Dedicated companies1, 3 A2M Pharma GmbH Monheim Adhesys Medical GmbH Aachen Affectis Pharmaceuticals AG Dortmund AgroProtect GmbH Aachen AiCuris GmbH & Co. KG Wuppertal Algiax Pharmaceuticals GmbH Erkrath arrows biomedical Deutschland GmbH Münster ARTES Biotechnology GmbH Langenfeld Autodisplay Biotech GmbH Düsseldorf Axiogenesis AG Köln AYOXXA Biosystems GmbH Köln Baliopharm GmbH Jülich BBT Biotech GmbH Baesweiler BIBITEC Gesellschaft für Prozessentwicklung mbH Bielefeld BioCheck GmbH Münster Biofrontera AG Leverkusen BioPIT Mining Company GmbH Münster BioSolveIT GmbH Sankt Augustin bitop AG Witten BSV Bioscience GmbH Baesweiler Carpegen GmbH Münster CellAct Pharma GmbH Dortmund CellSystems Biotechnologie Vertrieb GmbH Troisdorf Cevec Pharmaceuticals GmbH Köln Charles River Biopharmaceutical Services GmbH Erkrath ChemBiotech Münster Chimera Biotec GmbH Dortmund CIBUS Biotech GmbH Rheda-Wiedenbrück Cilian AG Münster CIRES cell & immune research services Dortmund Colbourne Pharmaceuticals GmbH Niederkassel Cube Biotech GmbH Monheim Cysal GmbH Münster Deutsche Saatveredelung GmbH Mechernich DIREVO Industrial Biotechnology GmbH Köln Epivios GmbH Düsseldorf evoxx technologies GmbH Monheim GEN-IAL GmbH Troisdorf IIT an der Universität Bielefeld GmbH Bielefeld IMAX Discovery GmbH Dortmund IMD Natural Solutions GmbH Dortmund InBio GbR Duisburg InfanDx AG Köln Informium AG Bergisch Gladbach Isoloid GmbH Düsseldorf Lead Discovery Center GmbH Dortmund Life & Brain GmbH Bonn Lonza Cologne GmbH Köln m2p-labs GmbH Baesweiler/Aachen Matricel GmbH Herzogenrath MetaVi Labs GmbH Witten miacom diagnostics GmbH Düsseldorf MILTENYI BIOTEC GmbH Bergisch Gladbach MLM Medical Labs GmbH Mönchengladbach Molekular Biologisches & Biochemisches Labor Dr. Bartling GmbH Bielefeld Morphoplant GmbH Bochum

p. 39 p. 39 p. 39 p. 59 p. 40 p. 40 p. 40 p. 29 p. 53 p. 41 p. 29 p. 41 p. 29 p. 30 p. 41 p. 42 p. 53 p. 53 p. 42 p. 42 p. 30 p. 43 p. 30 p. 31 p. 31 p. 43 p. 43 p. 44 p. 31 p. 54 p. 59 p. 54 p. 54 p. 55 p. 63 p. 55 p. 55 p. 44 p. 44 p. 45 p. 32 p. 56 p. 45 p. 45 p. 46 p. 32 p. 46 p. 46

1 List of dedicated biotechnology companies in the fiscal year 2015

multiBIND biotec GmbH Köln MykoMax GmbH Wuppertal NEO New Oncology AG Köln NeraCare GmbH Bönen NEUWAY Pharma GmbH Bonn Nexigen GmbH Köln PAIA Biotech GmbH Köln PAION AG Aachen Pharmedartis GmbH Aachen Phytowelt GreenTechnologies GmbH Nettetal PL BioScience GmbH Aachen PlasmidFactory GmbH & Co. KG Bielefeld Protagen AG Dortmund Protagen Protein Services Dortmund Protectimmun GmbH Gelsenkirchen PS Biotech GmbH Aachen QIAGEN GmbH Hilden QLAYM Healthcare AG Düsseldorf Ridom GmbH Münster Rigontec GmbH Bonn Saaten-Union BIOTEC GmbH Leopoldshöhe SanguiBioTech GmbH Witten Senzyme GmbH Troisdorf SeSaM-Biotech GmbH Aachen Sibion Biosciences GmbH Bonn SIT Soft Intelligent Therapeutics GmbH & Co KG Dortmund Sividon Diagnostics GmbH Köln Soluventis GmbH Bochum Squarix GmbH Marl Syntab Therapeutics GmbH Aachen Sysmex Partec GmbH Münster TaconicBiosciences GmbH Köln Transimmune AG Düsseldorf vivo Science GmbH Gronau W42 Industrial Biotechnology GmbH Marl WeissBioTech GmbH Ascheberg XanTec bioanalytics GmbH Düsseldorf Xell AG Bielefeld

p. 56 p. 59 p. 47 p. 47 p. 47 p. 32 p. 48 p. 48 p. 60 p. 33 p. 33 p. 48 p. 33 p. 49 p. 34 p. 49 p. 63 p. 60 p. 49 p. 56 p. 57 p. 50 p. 50 p. 50 p. 34 p. 51 p. 34 p. 35 p. 51 p. 35 p. 57 p. 35 p. 36

Other biotechnologically active companies2, 3 Bayer AG Cellex Gesellschaft für Zellgewinnung mbH Evonik Degussa GmbH Evonik Industries AG German Seed Alliance GmbH Grünenthal GmbH Henkel AG & Co. KGaA Janssen-Cilag GmbH Labopharm GmbH MEDIWISS Analytik GmbH Monsanto Agrar Deutschland GmbH Octapharma GmbH Pharma Waldhof GmbH Syngenta Seeds GmbH Taros Chemicals GmbH & Co. KG UCB GmbH W. von Borries-Eckendorf GmbH & Co. KG

Leverkusen p. 65 Essen Essen Köln Aachen Düsseldorf Neuss Bönen Moers Düsseldorf Langenfeld Düsseldorf Bad Salzuflen Dortmund Monheim Leopoldshöhe

p. 65 p. 65 p. 66 p. 66 p. 66 p. 67 p. 67 p. 67 p. 68 p. 68 p. 68

1 2 OECD Definition page 72 3 including company sites in NRW that are not headquarters and are therefore not accounted as NRW-based companies in the annual study by “BIO Deutschland e.V.”

Non-specific Services 28

BIO.NRW

non-specific services

ARTES Biotechnology is an independent technology provider for the pharmaceutical industry. Our business focus is on: • vaccine development (VLP technology) • process development of biopharmaceuticals • transfer of biosimilar processes Our technologies have resulted in innovative products marketed worldwide. WHO

recommendation, international registration, EMA resp. FDA approval and GRAS certification are achieved in international collaborations. Expression platforms include high yield yeasts and E. coli system for efficient protein production. Our unique chimeric virus like particle (VLP) platform METAVAX® is best suited for the development of highly immunogenic vaccines in human and animal health. Our proprietary technologies ensure freedom-to-operate and reliable, competitive production of innovative targets marketed worldwide.

AYOXXA Biosystems GmbH is an international biotech company based in Cologne (Germany) with offices in Boston (USA) and Singapore. LUNARIS™ is AYOXXA’s innovative, patented beads-on-a-chip technology platform to analyze picogram amounts of multiple biomarkers in biological samples. It delivers a high-quality immunoassay

for sample volumes down to single-digit microliter, greatly expanding the types and number of samples from which scientists can gain insights. AYOXXA opens protein multiplexing opportunities to biomedicine, all the way from basic research to clinic and translational discoveries covering ophthalmology, mouse-to-man and immunooncology applications.AYOXXA offers a selection of Multiplex detection kits, Control & Analysis Software. With the introduction of the AYOXXA Reader AR01, the company now provides a fully integrated solution for LUNARIS™ multiprotein analysis.

BBT Biotech GmbH produces freeze-dried viable bacteria (probiotics like lactobacilli, bifidobacteria, yeasts) and metabolites not only in bulk but also in finished dosage forms to the pharmaceutical and healthfood industriy. The fermenter capacity is up to 18.000 l. The downstream process is based on sepa-

rators, filtration systems, chromatography and freeze dryers. On the basis of individual needs BBT Biotech GmbH also offers active pharmaceutical ingredients like thrombolytics (streptokinase, urokinase), fertility hormones (HCG, HMG, FSH), inhibitors (Aprotinin, UTI) and others (Hyaluronidase, Corticotrophin).

Name ARTES Biotechnology GmbH Address Elisabeth-Selbert-Str. 9 Postal Code/City 40764 Langenfeld Fon Fax E-Mail Internet

+49 2173 27587-0 +49 2173 27587-77 info@artes-biotechnology.com www.artesbiotechnology.com Employees 22 Founded (year) 2002

Name AYOXXA Biosystems GmbH Address Nattermannallee 1 Postal Code/City 50829 Köln Fon Fax E-Mail Internet

+49 221 222529-0 +49 221 222529-11 info@ayoxxa.com www.ayoxxa.com

Employees 35 Founded (year) 2010

Name BBT Biotech GmbH Address Arnold-Sommerfeld-Ring 28 Postal Code/City 52499 Baesweiler Fon Fax E-Mail Internet

+49 2401 93310-0 +49 2401 93310-90 office@bbt-biotech.de www.bbt-biotech.de

Employees 30 Founded (year) 1999

BIO.NRW

non-specific services

Name BIBITEC GmbH

Address Universitätsstr. 25 Postal Code/City 33615 Bielefeld Fon +49 521 106-6326 Fax +49 521 106-156233 Internet www.bibitec.de Employees 10 Founded (year) 2001

BIBITEC Gesellschaft für Prozessentwicklung mbH is specialized in the production and purification of proteins (e.g. hormones, mAbs) derived from mammalian cell cultures. One major achievement was an erythropoietin (EPO) project that involved the process development and the GMPcompliant production of an EPO biosimilar for use in phase III clinical trials.

Name CellSystems Biotechnologie Vertrieb GmbH Address Langeler Ring 5 Postal Code/City 53842 Troisdorf Fon Fax E-Mail Internet

+49 2241 25515-0 +49 2241 25515-30 info@cellsystems.de www.cellsystems.de

Founded (year) 1992

Since its formation CellSystems ® has been a reliable partner for the life science community. CellSystems offers highly sophisticated research products, including EU validated 3D in vitro skin models for research and toxicology assays that were developed and are produced at our onsite laboratories. Additionally, CellSystems offers a wide range of contract services.

Name Charles River Biopharmaceutical Services GmbH Address Max-Planck-Str. 15a Postal Code/City 40699 Erkrath Fon Fax E-Mail Internet Employees Founded (year)

+49 211 9255-300 +49 211 9255-333 newlabinfo@crl.com www.criver.com 150 1993

Charles River Biopharmaceutical Services GmbH is a leading contract service organization providing innovative and tailor-made solutions for the quality control of biopharmaceuticals. We operate in full compliance with the GMP/GLP standards. Our testing facilities in Erkrath and Köln, Germany are part of a

The entire production and purification process was successfully transferred for large-scale production leading to one of the first successful approvals of a biosimilar in Europe. In 2012 BIBITEC became part of Nordmark Arzneimit tel GmbH & Co. KG , Uetersen. In cooperation with Nordmark and other validated partners BIBITEC provides all activities from “gene to product” including cell line and process development, GMP production, fill-and-finish and analytics.

In 2010, we opened our new clean room laboratories to meet the growing demands for various 3D tissue models and services. Today, our portfolio comprises a wide range of products for cell biology research and in vitro toxicology studies. CellSystems is certified ISO 9001:2008.

global scientific network offering services that span the entire drug development process. This allows us to provide our clients with more flexibility, experience and expertise to maximize resources and optimize results based on their specific program needs. Our services include: cell bank testing; analysis and clearance validation of contaminants and impurities (residual DNA, host cell proteins and endotoxins); safety studies for viruses and prions; characterization of the final product, lot release testing; bioassays and stability studies.

BIO.NRW

non-specific services

ics, immunogenicity assessment, stability testing and biomaker quantification.

Name Chimera Biotec GmbH Address Emil-Figge-Str. 76a Postal Code/City 44227 Dortmund

Chimera Biotec is the leading provider of ultra sensitive immunoassay development and bioanalytical sample testing. Chimera provides customized services as well as target quantification based on in house assays. Chimera Biotec manufactures and markets ultra sensitive Immuno-assays for pharmacokinetics, pharmacodynam-

Fon Fax E-Mail Internet

+49 231 9742-840 +49 231 9742-844 info@chimera-biotec.com www.chimera-biotec.com

Employees 20 Founded (year) 2000

industry. Fokus is analysis and product development to identify e.g. animal species, species of plants, GVO, allergens.

Name CIBUS Biotech GmbH Address Amselweg 1 Postal Code/City 33378 Rheda-WiedenbrĂźck Fon Fax E-Mail Internet

Main activities of the CIBUS Biotech GmbH are the development and application of molecular analyses for the examination of processed food, feed, or their single components as well as other products from pharmacological, cosmetic, paint or paper

Employees 7 Founded (year) 2001

are manufactured in-house and sold to scientific labs.

Cube Biotech is a provider for protein expression, purification, and crystallization services with a focus on the pharmaceutically relevant class of membrane proteins. Our services are complemented by affinity tag-based and protein-specific chromatography matrices to offer a unique solution. Dedicated products for protein purification and membrane protein crystallization

+49 5242 40556-0 +49 5242 40556-270 info@cibus-biotech.de www.cibus-biotech.de

Name Cube Biotech GmbH Address Alfred-Nobel-Str. 10 Postal Code/City 40789 Monheim Fon Fax E-Mail Internet

+49 2173 99373-0 +49 2173 99373-99 contact@cube-biotech.com www.cube-biotech.com

Employees 10 Founded (year) 2012

BIO.NRW

non-specific services

Name Lonza Cologne GmbH

Address Nattermannallee 1 Postal Code/City 50829 Köln Fon +49 221 99199-190 E-Mail info.cologne@lonza.com Internet www.lonza.com/research Employees 105 Founded (year) 1998

Lonza Cologne offers products for various uses, such as disinfectants and detergents in hospitals or pool areas, in pesticides against snails, in sports and energy drinks (vitamin B3, L-Carnitine) or in body lotions as emulsifying agents. Lonza Cologne develops and commercializes non-viral gene transfer products for primary cells and hard-to-transfect cell lines. With Lonza’s Nucleofector™ Technol-

Name Miltenyi Biotec GmbH Address Friedrich-Ebert-Str. 68 Postal Code/City 51429 Bergisch Gladbach Fon Fax E-Mail Internet

+49 2204 83066-540 +49 2204 8519-7 macs@miltenyibiotec.de www.miltenyibiotec.com www.miltenyi.tv Employees 1,400 Founded (year) 1989

Miltenyi Biotec, is a diversified biotechnology group of companies with a business focus on cellular technologies. M.B. produces and markets state-of-the-art products and technologies for cell separation, cell biology, related molecular biology applications. M.B. focuses on stem cell isolation, immune therapies, tissue replacement, with devices and biological

Name PAIA Biotech GmbH Address Gottfried Hagen Str. 60-62 Postal Code/City 51105 Köln Fon +49 221 16862380 E-Mail info@paiabio.com Internet www.paiabio.com Employees 4 Founded (year) 2014

PAIA Biotech GmbH offers assays for the rapid quantification of antibodies and proteins based on its proprietary assay technology. It features bead-based immunoassays with fluorescence detection in specially designed 384-well microplates which drastically simplify the workflow. The

ogy, the functionality of different genes can be analyzed in biologically relevant cell types. These results help identify possible new pharmaceuticals and therapies, for example to fight cancer or cardiovascular diseases. In addition, Cologne is the German distribution center for further Lonza businesses such as endotoxin detection, health and hygiene, industrial conservation, material preservation, nutrition and agriculture.

reagent kits for clinical and research use. Miltenyi Biotec also offers in cooperation with nanoPet pharma preclinical imaging agents – the Viscover™ Imaging portfolio. Another asset recently included into the program is lentiviral technology for cell and gene therapy applications. The CliniMACS® Technology allows clinicians to separate specific cell types to cure particular diseases. Acquiring OWL biomedical, Inc., Miltenyi Biotec has completed its portfolio by microchip-based cell sorting systems using fully-closed cartridges in an easy-to-use-format, applicable to the research and clinical cell therapy markets.

assays are amenable to automation and run on standard plate readers or fluorescence microscopes. PAIA Biotech focuses on products for screening applications with limited sample volume and high throughput requirements, e.g. in early cell line development. In addition to off-the-shelf products for IgG and IgG fragments PAIA Biotech GmbH also offers custom assay development. PAIA Biotech GmbH was founded in 2014 and is based at the RTZ in Cologne.

BIO.NRW

non-specific services

BioScience WE DELIVER CELL SOLUTIONS

tion of basic research into cell therapy. PL BioScience has a broad expertise concerning human platelet lysate as a better alternative to fetal bovine serum. PL BioScience offers diverse platelet lysates and platelet lysate derived products, e.g. a patent-protected 3D cell culture system.

PL BioScience is a young, ambitious and dynamic life science startup offering a portfolio of novel products and innovative technologies for human cell expansion in research and clinical applications. The company aims to accelerate the transla-

PlasmidFactory is the leading contract manufacturer for plasmid and minicircle DNA. The so-called ‘In Stock products’ are complementing the product portfolio: these plasmids are always in stock and are usually shipped within 48 hours of order.

Protagen Protein Services (PPS) is a leading contract research organization with an large international customer base in the field of Protein Analytics of biotherapeutics. With more than 17 years of experience in business, PPS is able to offer a comprehensive, GMP compliant spectrum of state of the art analytical methods, ensure the highest quality for the identification and structural

Name PL BioScience GmbH

Address Dennewartstraße 25-27 Postal Code/City 52068 Aachen Fon Fax E-Mail Internet

+49 241 95719-100 +49 241 95719-109 info@pl-bioscience.com www.pl-bioscience.com

Founded (year) 2015

Presently the following In Stock products are available: various reporter-gene plasmids and minicircles, pDG plasmids for the AAV virus production and pEPI /pEpito plasmids with S/MAR elements. PlasmidFactory’s research and development as well as its complete service branches are based in Germany. With various research projects and co-operations, PlasmidFactory is the driving force in the development of gene vectors.

Name PlasmidFactory GmbH & Co. KG Address Meisenstr. 96 Postal Code/City 33607 Bielefeld Fon Fax E-Mail Internet

+49 521 2997-350 +49 521 2997-355 info@plasmidfactory.com www.plasmidfactory.com

Employees 16 Founded (year) 2000

characterization incl. modification of new biological entities as well as biosimilar products. Comprehensive proteome studies and differential protein display techniques are offered in addition for example to support up and downstream process optimization of biotherapeutic production. PPS combines unique expertise in e.g. bioinformatics for protein mass spectrometry with a long track record in protein chemistry and protein analytics. PPS provides you with the full range of services, from drug discovery and development to release testing and regulatory compliance under ICH Q6B.

Name Protagen Protein Services GmbH Address Postal Code/City Fon Fax E-Mail

Otto-Hahn-Straße 15 44227 Dortmund +49 231 9742-6100 +49 231 9742-6149 contact@ProtagenProtein Services.com Internet www.ProtagenProtein Services.com Employees 70 Founded (year) 1997

BIO.NRW

non-specific services

Name PS Biotech GmbH

Address Kaiserstrasse 100 Postal Code/City 52134 Herzogenrath Fon Fax E-Mail Internet

+49 241 8946441-0 +49 241 8946441-99 info@psbiotech.com www.psbiotech.com

Founded (year) 2013

PS Biotech GmbH is a German developer and producer of polymer based release systems for biotechnological application. Recently the company expanded and moved its headquarter to Herzogenrath. PS Biotech offers unique solutions to enable strain developers and enzyme producers to optimize their screening processes. The product portfolio ranges from the well-known Feed Plate®, deepwell microti-

Name Squarix GmbH biotechnology Address Elbestr. 10 Postal Code/City 45768 Marl Fon Fax E-Mail Internet

+49 2365 915-278 +49 2365 915-254 info@squarix.de www.squarix.de

Employees 8 Founded (year) 1992

Name Sysmex Partec GmbH – Branch Office Münster (Headquarter: Am Flugplatz 13, 02828 Görlitz) Address Otto-Hahn-Str. 32 Postal Code/City 48161 Münster Fon +49 3581 8746-0 Fax +49 3581 8746-70 E-Mail info@sysmex-partec.com Internet www.sysmex-partec.com Employees 195 worldwide Founded (year) 1967

Squarix GmbH is a privately-held primary manufacturer of high purity Discovery Chemicals and Immunoreagents. Since 1992, Squarix produces a broad product line of compounds that include innovative building blocks, reactive intermediates, natural products and derivatives, screening

ter plates releasing glucose for fed-batch emulated high throughput screenings to tailor made solutions. The products enable obtaining of robust, process-near conclusions during screening, resulting in an optimized scale-up process of bio production. Synchronization of physiological conditions in screening and production leads to reliable high quality results and thus immensely increases the efficiency within the scope of screening and bio production.

compounds for drug discovery industry and reagents for life science applications comprising antibodies, metabolic intermediates, fluorescent dyes & probes and different affinity matrices for proteins and cells. Moreover, Squarix is a custom producer of polyclonal and monoclonal antibodies for biomedical research and offers all type of immunoanalytical services in the field of antibody technology.

immunology, cell biology, microbiology, biotechnology, agrosciences, plant breeding, aquaculture and in pharmaceutical, food and beverage industries.

Sysmex Partec is the collaboration between Partec, a worldwide leading pioneer, developer and manufacturer of flow cytometry systems and Sysmex Corporation, a leading international supplier of in vitro diagnostic products. Sysmex Partec products are used in a wide range of applications in healthcare,

BIO.NRW

non-specific services

ries and six breeding facilities in the U.S. and Europe and maintains distributor relationships in Asia.

Address Neurather Ring 1 Postal Code/City 51063 Köln

Taconic Biosciences is a global provider of genetically engineered rodent models and services. Founded in 1952, Taconic helps the biotechnology and pharmaceutical communities acquire, custom generate, breed, precondition, test, and distribute highly relevant research models worldwide. Specialists in Precision Research Models and GEMs Design & Management, Taconic operates three service laborato-

Fon Fax E-Mail Internet

+49 221 96453-10 +49 221 96453-21 info@taconic.com www.taconic.com

Employees 80 Founded (year) 1952

nology. In addition, vivo Science can also include immunological tests into standard toxicity studies for a medicinal product. vivo Science will provide GLP and GMP compliant, validated study protocols and will assist you in setting up a customized test program for your special requirements. vivo Science is a privately held CRO for preclinical studies focussing on the immune system. For years now, all regulatory agencies such as FDA or EMA very much enforce the testing of immunotoxicity (ICH-S8) and immunogenicity (ICH-S6) of new drug candidates, especially if derived from biotech-

Name Taconic Biosciences GmbH

Name vivo Science GmbH Address Fabrikstr. 3 Postal Code/City 48599 Gronau Fon Fax E-Mail Internet

+49 2562 8170-0 +49 2562 8170-19 info@vivoscience.de www.vivoscience.de

Employees 20 Founded (year) 2001

Name XanTec bioanalytics GmbH Address Merowingerplatz 1a Postal Code/City 40225 Düsseldorf XanTec bioanalytics specializes in biosensors and bio-nanocoatings. The company’s core competence are bioinert and bioactive nanocoatings for biomedical and bioanalytical applications. Products are SPR biosensor systems, SPR or other biosensor chips and coated slides for protein and DNA microarrays.

Fon Fax E-Mail Internet

+49 211 9936-4744 +49 211 9936-4746 info@xantec.com www.xantec.com

Employees 10 Founded (year) 1997

BIO.NRW

non-specific services

Name Xell AG Address Postal Code/City Fon Fax E-Mail Internet

Alte Verler Str. 1 33689 Bielefeld +49 521 96989-200 +49 521 96989-201 info@xell.ag www.xell.ag

Employees 22 Founded (year) 2009 as TeutoCell AG, renamed in 2014

Xell is an experienced partner for companies in the biotech and pharmaceutical industry providing them with highly-efficient solutions in cell culture technology. With years of industry experience, we bring our extensive expertise in high performance media and feed development, and apply our powerful

analytical tools for in-depth characterization of biological systems and pharmaceutical proteins, guaranteeing optimal solutions for our customersâ&#x20AC;&#x2122; bioprocesses. Based on our proprietary technology, Xell has developed a wide range of customized as well as commercial high-performance culture media, supplements and feeds for specialized production cell lines including CHO, hybridoma and HEK. Chemically defined and free of animal components, our products meet or exceed all necessary quality standards required for GMP manufacturing processes.

BIO.NRW

non-specific services

BIO.NRW

Health and Medicine (including Animal Health) 38

BIO.NRW

A2M Pharma is a spin-off from Schwarz Pharma with the aim of developing the most promising projects of Schwarz Pharma’s former R&D pipeline that was abandoned for strategic reasons following its merger with UCB. This portfolio includes projects in neurology and pain. A2M Pharma develops these projects until clinical proof of con-

Adhesys Medical develops fully synthetic, biodegradable surgical adhesives. Based on a polyurethane platform technology two products are currently under development: The first has been designed for dermal use, to close a great variety of topical wounds faster, more accurately and with fewer complications. The Second is designed for use inside the body: either

health and medicine

cept which will then be out-licensed or partnered. The current lead projects focus on the treatment of Parkinson’s disease and are supported by the Michael J Fox Foundation. A small molecular modulator of lipid rafts is in preclinical development as an α-synuclein aggregation inhibitor for disease modifying treatment of Parkinson’s Disease and potential for other protein aggregation disorders. The second lead project focusses on the treatment of dyskinesias and involves a isorotigotine for transdermal delivery.

as an adhesive, to seal areas of leakage or re-attach tissue, or as a hemostat, to stop bleeding. The company was founded in 2013 in Aachen, Germany. In February 2014, the founders closed a 7-digit seed investment round with S-UBG, KfW and a group of private investors. In April 2014 the team won the Rice Business Plan Competition in Houston, Texas and expanded to the United States after closing a further investment round of $2.7 Mio. with US investors.

its programs at late discovery/early development stage. The company is located in Dortmund, Germany, and is looking for academic and industrial collaborations for testing its frontrunner compound.

Affectis is a pharmaceutical company developing novel proprietary drugs for the treatment of neurodegenerative and neuroinflammatory diseases based on pioneering findings in the field of P2X7 receptors. Affectis will partner or license

Name A2M Pharma GmbH Address Alfred-Nobel-Str.10 Postal Code/City 40789 Monheim Fon +32 484 26 55 06 E-Mail info@a2m-pharma.com Internet www.a2m-pharma.com Employees 3 Founded (year) 2009

Name Adhesys Medical GmbH

Address Pauwelsstraße 17 Postal Code/City 52074 Aachen Fon +49 241 41250320 Internet www.adhesys-medical.com Employees 13 Founded (year) 2013

Name Affectis Pharmaceuticals AG

Address Otto-Hahn-Str. 15 Postal Code/City 44227 Dortmund Fon Fax E-Mail Internet Founded (year)

+49 231 97427000 +49 231 97427039 info@affectis.de www.affectis.com 2006

BIO.NRW

health and medicine

AiCuris is a pharmaceutical company focused on discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. The most advanced projects in the company’s pipeline are Letermovir (licensed

to MSD), designed to inhibit the viral terminase of the human cytomegalovirus, achieved positive results in the Phase 3 study, and Pritelivir, a helicase-primase inhibitor, being developed to treat herpes simplex virus type 1 and type 2 infections. Pritelivir has succesfully completed a Phase 2 trial in genital herpes. Phase 1 development of a topical formulation for the treatment of labial herpes is also completed. Further programs are AIC499, a resistance-breaking gram-negative antibiotic and AIC649, an immune modulator for the treatment of hepatitis B.

Algiax Pharmaceuticals GmbH is a biotechnology company that was established in April 2011. It is dedicated to the discovery and development of innovative products in the field of nervous system disease with a strong focus on neuropathic pain. The company’s lead compound AP-325 is currently in clinical development. The comprehensive Phase I program has been finalized (>100 male and fe-

male subjects exposed to AP-325) and shows a good safety and tolerability profile in healthy volunteers after single and multiple dosing. The human PK profile of AP-325 is compatible with once-a-day administration and fast onset of action. A broad patent portfolio covering major commercial markets is solely owned by Algiax. The primary indication is neuropathic pain, the secondary indication is spinal cord injury for which Algiax has an orphan drug designation. Altogether, Algiax is well positioned to take advantage of the market opportunity not only in the field of neuropathic pain but also in other unmet medical diseases.

arrows biomedical Deutschland carries out contract research and clinical routine analyses, and also pursues its own R&D projects. The firm’s areas of focus are primarily in the fields of molecular oncology and neurodegenerative disease. Its portfolio of molecular analytics includes RNA/ DNA. Services like RNA/DNA isolation,

microarrays(GenExpression, Array-CGH, ChIP on chip, DNA-Methylation-Microarrays), PCR (RT-qPCR) and bioinformatics. In the area of medical diagnostics, the portfolio includes routine analysis (testing for all clinical relevant biomarkers and the complete range of blood analysis), flow cytometry (NAVIOS), HPLC analysis, diagnostic microarrays, detection of freely circulating tumor cells, and chemosensitive analysis. Furthermore, FISH analysis, general microscopy with the Zeiss axio imager M 2 in combination with the MetaSystemsSoftware and Pyro- and Sanger sequencing.

Name AiCuris Anti-infective Cures GmbH Address Friedrich-Ebert-Str. 475 Postal Code/City 42117 Wuppertal Fon Fax E-Mail Internet

+49 202 31763-0 +49 202 31763-1177 info@aicuris.com www.aicuris.com

Employees 55 Founded (year) 2006

Name Algiax Pharmaceuticals GmbH Address Max-Planck-Str. 15a Postal Code/City 40699 Erkrath Fon Fax E-Mail Internet

+49 211 617851-15 +49 211 617851-50 info@algiax.com www.algiax.com

Employees 6 Founded (year) 2011

Name arrows biomedical Deutschland GmbH Address Postal Code/City Fon Fax E-Mail Internet

Heisenbergstraße 11 48149 Münster +49 251 534064-00 +49 251 534064-01 raem@arrows-biomedical.com www.arrows-biomedical.com

Employees 10 Founded (year) 2005

BIO.NRW

Axiogenesis is the leading provider of commercial-grade human induced pluripotent stem cell derived cells, which enable drug development. Validated assays for each cell type have been developed for advanced drug discovery, disease and tissue modeling, safety and toxicology. Our innovative and proprietary cells and assays accelerate

Baliopharm is a pharmaceutical company firstly offering services for the preclinical and clinical development of biopharmaceutical compounds and secondly dedicated to the development of new innovative biopharmaceutical compounds for the treatment of inflammatory diseases such as rheumatoid arthritis, Morbus Crohn and multiple sclerosis. Our lead product ATROSAB, a human-

Biocheck introduced Polycheck® Platform Technology as a tool for medical differential diagnosis. The multiparameter test device enables a serological quantitative allergy screening on the basis of solid phase Immuno-Assay-Technology using monoclonal antibody detection; colorcoded devices are presenting different allergen panels. For autoimmune diagnosis a quantitative screening for disease patterns is new family

health and medicine

and improve drug candidate selection, reduce time and thus increase drug development efficiency. The products encompass hiPSC-derived cardiac (Cor.4U®, vCor.4U & FibroCor.4U) and neural cells (Peri.4U, Dopa.4U, Astro.4U & CNS.4U). Products in development include iPSC-derived sensory, cortical and motor neurons as well as matured cardiomyocytes. As a result of our in-house assay capability, we can provide expert scientific support in order to facilitate selection and quick implementation of validated assays and technologies.

ized anti-TNF-receptor antibody, currently in phase I clinical studies, has been proven in head to head comparative, preclinical studies to be more safe and more efficacious as state of the art marketed products. In addition, Baliopharm´s service arm is GLP/GMP certified for analytics needed in preclinical and clinical studies We perform all kind of serum analytics needed for the development of biopharmaceutical compounds. We also offer a wide set of cell based potency assays for new biological as well as for biosimilar products.

member of Polycheck®. Quantitative evaluation is performed by picture scanning and calculation by Biocheck Imaging Software. The assay prodedure can be worked out manually or fully automated including matching with central Laboratory Information Systems (LIS).

Name Axiogenesis AG Address Nattermannallee 1 Gebäude S20 Postal Code/City 50829 Köln Fon Fax E-Mail Internet

+49 221 998818-0 +49 221 998818-10 info@axiogenesis.com www.axiogenesis.com

Employees 40 Founded (year) 2001

Name Baliopharm GmbH Address Karl-Heinz-Beckurts-Str. 13 Postal Code/City 52428 Jülich Fon Fax E-Mail Internet

+49 2461 6210-855 +49 2461 6216-687 pharma@baliopharm.de www.baliopharm.com

Employees 20 Founded (year) 2011

Name BioCheck GmbH Address Vorbergweg 41 Postal Code/City 48159 Münster Fon Fax E-Mail Internet

+49 251 2150-868 +49 251 2150-870 office@polycheck.de www.biocheck.de

Employees 18 Founded (year) 1999

BIO.NRW

health and medicine

Name Biofrontera AG Address Hemmelrather Weg 201 Postal Code/City 51377 Leverkusen Fon Fax E-Mail Internet

+49 214 87632-0 +49 214 87632-90 info@biofrontera.com www.biofrontera.com

Employees 57 Founded (year) 1997

Biofrontera AG is a biopharmaceutical company specializing on the development of drugs and medicinal cosmetics for the treatment of skin diseases and the regenerative care of damaged skin. Headquartered in Leverkusen, Germany, Biofrontera is publicly listed on the Frankfurt Stock Exchange (B8F). Biofrontera’s lead product Ameluz® is a prescription drug initially approved and

Name Carpegen GmbH Address Mendelstr. 11 Postal Code/City 48149 Münster Fon Fax E-Mail Internet

+49 251 980-2320 +49 251 980-2321 info@carpegen.de www.carpegen.de

Employees 10 Founded (year) 2001

Carpegen is a provider of high quality molecular diagnostics. The company focuses on developing real-time PCR assays and point-of-care (POC) diagnostics for the diagnosis of specific infections and the detection of genetic biomarkers. Carpegen has developed Carpegen ® Perio Diagnostics, a powerful real-time PCR based

Name CellAct Pharma GmbH Address Otto-Hahn-Str. 15 Postal Code/City 44227 Dortmund Fon Fax E-Mail Internet

+49 231 9742-6350 +49 231 9742-6355 info@cellact.eu www.cellact.eu

Employees 7 Founded (year) 2007

CellAct Pharma GmbH is a venture capital backed company focused on the development of innovative therapeutics for the treatment of cancers with high unmet need. The small molecule prodrug targeting Topoisomerase, CAP7.1, is currently in

marketed in Europe and now also approved in the U.S. in combination with the medical lamp BF-RhodoLED® for the treatment of actinic keratosis. Biofrontera is the first German biotech company to obtain centralized EU and U.S. approval for a medical device/ drug it has developed itself. Biofrontera also markets a dermatological range of cosmetics. The Belixos® products contain combinations of active herbal substances, relieve itching and redness and are used for the regenerative care of chronic skin conditions. The Belixos® Protect, a daily skincare for sun-damaged skin, complements this cosmetic line.

system that sets new standards in microbiological periodontal diagnostics. A main objective of Carpegen’s research program is to develop and out-license POC/PCR systems for diverse applications in medical and non-medical markets. Two joint R&D projects related to the development of innovative antibiotic resistance diagnostics and water analytics are currently being pursued with financial support of the state of North Rhine-Westphalia and the German Federal Ministry for Economic Affairs and Energy.

clinical Phase II study for the treatment of refractory biliary tract-, small-cell and non-small cell-lung cancers. European Medicines Agency has granted orphan drug designation to CAP7.1 for the treatment of refractory biliary tract cancers. The recent interim analysis of the ongoing phase II study in biliary tract cancer indication resulted in favor of CAP7.1 and met the primary objective of disease control including partial response and stable disease with tumor shrinkages.

BIO.NRW

CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system. CAP-GT is a regulatory endorsed expression platform for scalable viral vector production. CAP-GT suspension cells grow to high cell densities and show a broad viral propagation spectrum. Gene therapy vectors such as lentivirus (LV), adenovirus

health and medicine

(AV) and adeno-associated virus (AAV) can be produced at industrial scale. CAP-GT enables better scale-up and competitive production costs when compared to adherent cell culture systems. CAP-Go enables the production of proteins previously out of reach. The expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor made glycosylation of recombinant proteins. The cells highly efficiently produce a broad range of difficult to express glycoproteins and provide authentic human post-translational modifications. Follow CEVEC on LinkedIn.

Name CEVEC Pharmaceuticals GmbH Address Gottfried-Hagen-Str. 60-62 Postal Code/City 51105 Köln Fon Fax E-Mail Internet

+49 221 46020-800 +49 221 46020-801 info@cevec.com www.cevec.com

Founded (year) 2003

Name Cilian AG Address Johann-Krane-Weg 42 Postal Code/City 48149 Münster

Cilian AG is a biotechnology company developing and marketing a novel expression system. The company uses a species of Ciliates, a eukaryotic single-cell organism, for the production of vaccines, monoclonal antibodies and therapeutic enzymes.

Fon Fax E-Mail Internet

+49 251 6203-114 +49 251 6203-116 info@cilian.de www.cilian.de

Employees 14 Founded (year) 2001

Name CIRES cell + immune research services GmbH

CIRES is experienced in all kinds of cell culture techniques, ranging from generation of hybridomas, culture of mammalian cells in general and the culture of lines of transgenic cells.

Address BioMedizinZentrum Bochum Universitätsstrasse 136 Postal Code/City D-44799 Bochum Fon +49 23493696536 Fax +49 23493696538 E-Mail info@cires.de Internet www.cires.de Employees 3 Founded (year) 2001

BIO.NRW

health and medicine

Name Colbourne Pharmaceuticals GmbH Address Viktoriaweg 7 Postal Code/City 53859 Niederkassel Fon +49 2208 770505 Fax +49 221 470-5092 E-Mail gschwarz@colbournepharma.com Employees 6 Founded (year) 2008

Colbourne Pharmaceuticals develops and produces drugs for the treatment of inborn errors in metabolism and offers diagnostic services for molybdenum cofactor deficiency and sulphite oxidase deficiency. Colbourne Pharmaceuticals provides services to Alexion Pharmaceuticals Inc. in the development of cPMP for the treatment of molybdenum cofactor type A deficiency.

Name InfanDx AG Address Balthasarstr. 18 Postal Code/City 50670 Köln Fon Fax E-Mail Internet

+49 221 30089783 +49 221 2851975 info@infandx.de www.infandx.com

Employees < 10 Founded (year) 2010

First diagnostic test to detect perinatal asphyxia (PA, oxygen deficit during birth) and related braindamage. PA is very prevalent in childbirth worldwide with 0.5-4% of births affected. Typical outcome brain damage results in e.g. cerebral palsy/spasticism, blindness etc. Therapy is available and reimbursed since 2010, but needs to be started within 6 h

Name Lead Discovery Center GmbH Address Otto-Hahn-Str. 15 Postal Code/City 44227 Dortmund Fon Fax E-Mail Internet

+49 231 9742-7002 +49 231 9742-7039 info@lead-discovery.de www.lead-discovery.de

Employees 63 Founded (year) 2008

Bridging the gap between academic discoveries and pharmaceutical development. Active in the field of drug discovery, LDC transforms promising early stage projects into marketable assets providing industry with high-quality leads with proof-of-concept in animals. These small molecule drug discovery projects are conducted in close

after delivery. No suitable diagnostic exists today. Thus, ca. half of cases are not treated. Still, up to 15 unnecessary treatments are applied to cure one patient. InfanDx develops the first test to be applied immediately after birth. The immunology like format uses a small blood sample only. Technology origin is metabolomics research. InfanDx seeks partnerships as. – pharma-partnering, („companion diag nostic“, therapy monitoring) – manufacturer of point-of-care device – marketing co-operations

collaboration with world-class academic researchers from LDC’s broad network including the Max Planck Society, Helmholtz Association and numerous universities. The LDC team consists of experts with solid industry experience in project management as well as Screening, Cellular Biology, Pharmacology and Medicinal Chemistry. LDC has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Merck, Qurient und Roche as well as leading academic drug discovery centers worldwide.

BIO.NRW

LIFE&BRAIN is a development-stage biomedical enterprise serving as commercial hub of the University of Bonn Medical Center. Integrating a unique set of expertise in Genomics, Transgenics, Cellomics and Neurocognition, we aim at delivering the next generation of products for disease modeling and prediction, compound development and tissue regeneration.

Matricel GmbH develops and produces innovative medical class III collagen implants and biomatrices for applications in medicine and biotechnology. Matricel proprietary technologies are the key to successfully produce biocompatible and biodegradable matrices in a wide range of modifications suitable for the cultivation with human cells in tissue engineering and

MetaVì Labs provides drug discovery services for cell migration inhibitors to biotech and pharmaceutical companies and research labs worldwide. MetaVì Labs’ process is based on a 3-D collagen matrix system that recapitulates

health and medicine

Products and services include genome and gene expression analysis, industry scale human stem cell-based models of neurologic diseases for compound development as well as electrophysiology services to characterize small molecules in target engagement, efficacy and potency in human and rodent models.

Name Life & Brain GmbH Address Sigmund-Freud-Str. 25 Postal Code/City 53127 Bonn Fon Fax E-Mail Internet

+49 228 6885-100 +49 228 6885-101 info@lifeandbrain.com www.lifeandbrain.com

Employees 40 Founded (year) 2002

regenerative medicine. The products serve different medical fields like ACI-Maix and Cartimaix for tissue engineering of articular cartilage and other orthopedic applications and Remaix as a dental membrane for guided bone regeneration. Matricel´s product Optimaix is dedicated for research in 3D cell culture. Matricel has a promising product pipeline in further medical fields like dermal and nerve regeneration with customized scaffolds.

Name Matricel GmbH

Address Kaiserstr. 100 Postal Code/City 52134 Herzogenrath Fon +49 2407 5644-0 E-Mail info@matricel.com Internet www.matricel.com Employees 28 Founded (year) 2001

the tumor environment to measure live tumor cell migration. This is the only cell migration method that has been clinically validated for in vitro screening of drugs for antimetastatic effects. The company’s patent pending microscopy system automatically tracks thousands of cells as individuals as they migrate freely in 3-D collagen.

Name MetaVì Labs GmbH

Address Eichenkamp 10 Postal Code/City 46244 Bottrop Fon Fax E-Mail Internet

+49 2045 4133708 +49 2045 4133707 sales@metavilabs.com www.metavilabs.com

Founded (year) 2013

BIO.NRW

health and medicine

Miacom Diagnostics is specialized in developing next-level in vitro diagnostic tests for the identification of pathogens causing acute systemic diseases. Miacom improves critical patient care by providing rapid molecular diagnostic tools designed for routine use to promote more efficient antibiotic therapies and help healthcare organizations reduce costs. Our proprietary Direct Multiplex Imaging (DMI) assays deliver

results in less than 30 minutes directly from patient samples without need of tedious sample preparation or DNA amplification. In addition to the world´s only molecular diagnostic (MDx) test that identifies all relevant pneumonia-related bacteria directly from sputum, miacom offers CE & FDA cleared multiplex test for sepsis. Our latest innovation includes a fully automated rapid ID system that allows high-throughput MDx testing of several hundred samples per day. Since 2014 Fosun Diagnostics, the diagnostic division of Shanghai Fosun Pharmaceutical, is investor by miacom.

MLM Medical Labs is a CAP- and DIN EN ISO 15189-accredited, GLP-certified and CLIAregistered central and specialty lab dedicated exclusively to clinical trials. MLM offers the entire portfolio of service elements to support clinical trials: – Development and validation of special analytical methods – MLM Assembly Services® for global supply of sampling kits

– World-wide sample logistics – MLM Safeguard Box® for temperature protected sample shipments – Clinical chemistry, hematology, serology and urinalysis – Biomarker assays including multiplex panels – Long term cryo-storage of samples – Web Access - mlm online® MLM’s services are offered 365 days a year. We create a reliable partnership with our clients and our core values are: Scientific Excellence / Customized Solutions / Personal Accountability

Morphoplant GmbH is a bio-/ medtec company headquartered at the BioMedizinZentrum in Bochum and focused on the integration of biotech functionalities into medical devices. Laboratories equipped with state-ofthe-art technology for recombinant protein

production, protein chemistry, molecular and cell biology, isotope protein labeling/ monitoring and optical biosensor technology are available to our experienced and multidisciplinary R&D team. Morphoplant’s proprietary technologies provide our customers with ultrahydrophilic and osteophilic long-term storable metal implant surfaces and solutions for biocoating of a variety of implant materials with recombinant growth factors (bone/ vascular). Our outstanding expertise in surface functionalization, protein adsorption, kinetics monitoring and animal testing is also available for contract research..

Name miacom diagnostics GmbH Address Merowingerplatz 1a Postal Code/City 40225 Düsseldorf Fon +49 211 3015-5795 Fax +49 211 2989-143 E-Mail info@miacomdiagnostics.com Internet www.miacomdiagnostics.com Employees 10 Founded (year) 2006

Name MLM Medical Labs GmbH Address Dohrweg 63 Postal Code/City 41066 Mönchengladbach Fon Fax E-Mail Internet

+49 2161 4642102 +49 2161 4642190 kneuer@mlm-labs.com www.mlm-labs.com

Employees 41 Founded (year) 1993

Name Morphoplant GmbH Address Universitätsstr. 136 Postal Code/City 44799 Bochum Fon Fax E-Mail Internet

+49 234 7772870 +49 234 7772870-20 info@morphoplant.de www.morphoplant.de

Employees 14 Founded (year) 2002

BIO.NRW

NEO New Oncology GmbH is a molecular diagnostics company dedicated to the fast, reliable identification and interpretation of all therapy-relevant genomic changes in cancer patient samples. The proprietary technology platform “NEO” delivers clinically meaningful results from just one small sample, either a tissue paraffin block or blood. Based on advanced

NEUWAY Pharma GmbH, Bonn, Germany, is focusing on the preclinical and clinical development of innovative therapeutics for treatment of severe orphan brain diseases based on its proprietary CNS Drug Delivery Platform. The company also intends to partner

Nexigen GmbH leverages its extensive R&D experience in peptide therapeutics for the efficient discovery and rational development of peptide medicines (“NexiTides”) with qualified cellular mechanisms of action. Nexigen’s technologies give access to high value drug targets which pose signifi-

health and medicine

diagnostics combined with oncological expertise, “NEO” identifies all available treatment options ranging from standard therapies to clinical studies, enabling clinicians to fully understand individual cancer profiles and to make informed treatment decisions. NEO New Oncology is part of Siemens Healthineers.

Name NEO New Oncology GmbH Address Gottfried-Hagen-Str. 20 Postal Code/City 51105 Köln Fon Fax E-Mail Internet

+49 221 888 238-0 +49 221 888 238-22 info@newoncology.de www.newoncology.de

Employees 35 Founded (year) 2012

its drug delivery technology for application to proprietary compounds of pharmaceutical companies to exploit its therapeutic use in the field of CNS indications. Besides that NEUWAY initiated the development of a vaccine to treat a rare but frequently fatal neurological disease called progressive multifocal leucoencephalopathy (PML). The company is backed with venture capital from renowned investors and a strong board.

Name NEUWAY Pharma GmbH Address Ludwig-Erhard-Allee 2 Postal Code/City 53175 Bonn Fon Fax E-Mail Internet

+49 228 522798-0 +49 228 522798-99 info@neuway.de www.neuway-pharma.com

Employees 16 Founded (year) 2014

cant challenges to conventional discovery approaches. Targets include aberrantly activated intracellular disease pathways in so-called cancer stem cells, for which currently no treatment alternatives exist, but which are main drivers of tumor recurrence and spread. Nexigen was founded in 2007 and is headquartered at the BioCampus Cologne, Germany.

Name Nexigen GmbH Address Nattermannallee 1 Postal Code/City 50829 Köln Fon Fax E-Mail Internet

+49 221 337772-00 +49 221 337772-29 bdcontact@nexigen.de www.nexigen.de

Employees 23 Founded (year) 2007

BIO.NRW

health and medicine

PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs to be used in out-patient and hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic

drug candidate. Currently, remimazolam is in active Phase III clinical development for use in procedural sedation in the U.S. Remimazolam is partnered in the U.S., Canada, China, Russia (CIS), Turkey, the MENA region, and South Korea. PAION is headquartered in Aachen (Germany) with further sites in Cambridge (United Kingdom) and New Jersey (USA). PAION’s vision is to become an acknowledged “PAIONeer” in sedation and anesthesia. PAION is listed at the Frankfurt Stock Exchange (Prime Standard Regulated Market, Stock Symbol PA8, ISIN DE000A0B65S3).

Pharmedartis (PMA) develops next generation targeted therapies. This platform technology of Human Cytolytic Fusion Proteins (HCFP) has several advantages over wellreceived ADCs. A binder is recombinantly fused to a payload. This can be proteases,

RNases or kinases. Since the binder can be almost anything making it truly scalable. Human payloads should have much less side-effects. We look for partner interested in out-licensing opportunities for these first-in-class products. We develop CFPs to treat cancer, inflammation, auto-immune and skin diseases. 6 products are in preclinical testing. CFPs for clinical testing can be produced in Aachen in proprietary system at a state-of-the-art GMP facility of Fraunhofer Society, of which PMA is a spin-off. As a onestop-shop we provide full service from gene to biopharmaceutical product.

Name Paion AG Address Martinstr. 10-12 Postal Code/City 52062 Aachen Fon Fax E-Mail Internet

+49 241 4453-152 +49 241 4453-523 info@paion.com www.paion.com

Employees 39 Founded (year) 2000

Name Pharmedartis GmbH Address Forckenbeckstr. 6 Postal Code/City 52074 Aachen Fon Fax E-Mail Internet

+49 241 6085132-60 +49 241 6085132-66 mail@pharmedartis.de www.pharmedartis.de

Employees 5 Founded (year) 2007

Name Protagen AG

Address Otto-Hahn-Str. 15 Postal Code/City 44227 Dortmund Fon +49 231 9742-6300 E-Mail bd@protagen.com Internet www.protagen.com Employees 31 Founded (year) 1997

Protagen AG improves Personalized Patient Care Protagen is a diagnostics company that is a clear technology and IP leader in its field. We are focused on the development and commercialization of novel diagnostic tests for the diagnosis, disease stratification and therapy support in autoimmune disease. The Company’s goal is to facilitate thera-

peutic development and improve treatment strategies for autoimmune diseases, the 2nd most important pharma market today, with an initial focus on RA, SLE, SSc and similar disorders. We are adding a new dimension to the world of diagnostics and personalized therapy by enabling more successful drug development and better treatment strategies. Thus, based on our own IVD product sales and our pharma collaborations, Protagen is in position to capture its first mover advantage and claim a market leading position in this market.

BIO.NRW

Protectimmun GmbH is a biopharmaceutical R&D company focussed on new approaches in the prevention and therapy of allergic and chronic inflammatory diseases. Our innovative concept for product development is based on the identifica-

QIAGEN is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules

health and medicine

tion of natural substances and bacteria with immunomodulatory properties from particular farm environments which are selectively transferred into pharmaceutical applications. Promising candidates which were successfully tested in proofof-concept animal models of asthma are currently in mid- to late-stage preclinical development.

Name Protectimmun GmbH

Address UniversitĂ¤tsstr. 136 Postal Code/City 44799 Bochum Fon +49 234 97668275 E-Mail info@protectimmun.de Internet www.protectimmun.de Employees < 10 Founded (year) 2007

visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Further information can be found at www.qiagen.com

Name QIAGEN GmbH Address Qiagen Str. 1 Postal Code/City 40724 Hilden Fon Fax E-Mail Internet

+49 2103 29-0 +49 2103 29-22000 pr@qiagen.com www.qiagen.com

Employees > 4,600 worldwide Founded (year) 1984

Name SanguiBioTech GmbH Address Alfred-Herrhausen-Str. 44 Postal Code/City 58455 Witten

SanguiBioTech GmbH engages research and development of pharmaceutical, medical and cosmetic products. Many of their technologies are patented and unique.

Fon Fax E-Mail Internet

+49 2302 915200 +49 2302 915191 info@sangui.de www.sangui.de

Employees 6 Founded (year) 1995

BIO.NRW

health and medicine

binding sites two inactive compounds to cancer cells, where they combine to an active product initiating apoptotic processes. In parallel SIT develops novel intelligent and highly specific liposomal payloads on DNA basis for different diseases such e. g. Hepatitis B.

Name SIT - Soft Intelligent Therapeutics Biotech GmbH Address Otto-Hahn-Str. 15 Postal Code/City 44227 Dortmund Fon Fax E-Mail Internet

+49 231 97427252 +49 231 97427251 info@sit-biotech.com www.sit-biotech.com

Employees 6 Founded (year) 2010

Soft Intelligent Therapeutics (SIT) is a biotech company focused on personalized cancer treatments combining maximum efficacy with minimum side effects. The first product candidate of its targeted gene delivery platform is designed to separately and selectively deliver via two different

Sividon Diagnostics is a spin-off from Siemens Healthcare Diagnostics´ former research group in Köln. Its management team represents decades of professional experience in molecular diagnostics. Sividon develops and markets innovative products to improve the individualized selection of therapies in oncology. The company currently focusses on breast cancer, the

first product being EndoPredict®, a breast cancer test identifying those patients who can be cured with an antihormonal treatment and therefore be spared an aggressive chemotherapy. It is worldwide the first RNA-based diagnostic test for breast cancer that can be carried out in any wellequipped molecular pathology laboratory. Also, Sividon is a member of the European study group “RESPONSIFY – Genomebased biomarkers leading to validated molecular diagnostic tests for response prediction in breast cancer”. Since May 31, 2016 Sividon is part of the Myriad Genetics group.

The Soluventis-platform is based on the most powerful drug delivery system, an entirely new type of Nanocarrier characterized by incomparable high efficacy and a very good safety profile. The Soluventis Nanocarrier shields the transported siRNA, microRNA or peptides from blood and im-

mune system contact, and reaches reliable target organs including poorly vascularized tumor tissue. The targeting of metastases is excellent. The frozen Nanocarrier has a long shelf life in ampoules whereas in the organism it is completely eliminated within two days. Soluventis has a portfolio of oncologic siRNAs which significantly improve tumor reduction and elimination of metastases in xenograft models. In combination with the novel drug delivery system we offer a faster and more effective development of clinical candidates for pharmaceutical companies.

Name Sividon Diagnostics GmbH Address Nattermannallee 1 Postal Code/City 50829 Köln Fon Fax E-Mail Internet

+49 221 669561-00 +49 221 669561-99 info@sividon.com www.sividon.com

Employees 20 Founded (year) 2010

Name Soluventis GmbH Address Im Lottental 36 Postal Code/City 44801 Bochum Fax +49 234 32 29125 Fon +49 234 32 14191 E-Mail soeren.schreiber@ soluventis.de Internet www.soluventis.de

Founded (year) 2009

BIO.NRW

health and medicine

Syntab Therapeutics is committed to the exploration and development of innovative drugs against severe diseases such as cancer. Syntab’s synthetic antibodies exhibit all desirable properties of conventional antibodies while, at the same time, being significantly smaller chemically accessible molecules. The company strives for the

TRANSIM MUNE

Transimmune AG is developing novel immunotherapies based on its unique understanding of the physiologic processes underlying the activation of antigen presenting cells. This understanding derives from nearly 30 years of research into the mechanism of action behind Extracorporeal Photopheresis (ECP), arguably the first FDA-approved cellular immunotherapy. ECP is a highly success-

early out-licensing of product candidates after completion of the preclinical development. Syntab’s platform technology enables the chemical synthesis of highly effective drugs against severe diseases such as cancer. The flexibility of the technology is based on the application of diverse highly specific binders against specific cell surface proteins. Furthermore, the technology has the potential to vary the number and specific properties of binders and effectors that activate the immune system for each drug molecule.

ful immunological treatment used for many years, mainly in cutaneous T cell lymphoma (CTCL), graft versus host disease (GVHD) and organ transplant rejection. Transimmune has created two core technologies; Transimmunization and Transtolerization. These involve protocols for manipulating the immune system that have been reduced to practice through our mouse-to-man development platform, generating compelling preclinical proof-of-concept data. These technologies have the potential to significantly enhance current ECP practice as well as drive its application more broadly into numerous other indications.

Name Syntab Therapeutics GmbH Address St.-Jobser-Straße 56 Postal Code/City 52146 Würselen Fon +49 171 6558374 E-Mail info@syntab-therapeutics. com Internet www.syntab-therapeutics. com Employees < 10 Founded (year) 2010

Name Transimmune AG

Address Königsallee 90 Postal Code/City 40212 Düsseldorf Fon Fax E-Mail Internet

+49 211 64136110 +49 211 8693 1614 info@transimmune.de www.transimmune.com

Founded (year) 2012

BIO.NRW

Industrial Biotechnology 52

BIO.NRW

industrial biotechnology

numerous benefits to biocatalysis, the functionalisation of solid surfaces and screening applications. With its custom-tailored products and services, Autodisplay Biotech is an ideal partner for leading companies in the chemical, pharmaceutical and biotechnology industries. Autodisplay Biotech GmbH is a biotechnology company commercializing its proprietary expression platform for the display of heterologous proteins or peptides on the surface of gram negative bacteria. This cell surface display technology provides

Name Autodisplay Biotech GmbH Address Merowinger Platz 1a Postal Code/City 40225 Düsseldorf Fon Fax E-Mail Internet

+49 211 20951378 +49 211 99459636 info@autodisplay-biotech.com www.autodisplay-biotech.com

Employees 9 Founded (year) 2008

bitop AG focuses on the development, manufacture and marketing of medical devices and high quality active ingredients for cosmetics. The technological base of bitop AG’s business are substances from the class of extremolytes, in particular the compound Ectoin®. Extremolytes are natural protective

molecules that are formed by microorganisms and plants. bitop AG produces such extremolytes in an industrial scale in its own facility in Witten according to its proprietary biotechnological production processes. bitop AG has developed Ectoin®-containing medical devices for the symptomatic treatment of cough and cold, allergies, dry mucosa, inflammatory skin diseases and airway diseases. The marketing and sale of these medical devices is performed by licensees from the pharmaceutical industry. Currently, bitop’s medical devices are available in more than 45 countries worldwide.

BSV BioScience GmbH was founded in Oct. 2007 in Baesweiler, near the historical city of Aachen. Since June 2010, the company manufactures and markets biological pharmaceutical active ingredients for different therapeutic areas. One of our key strengths is based on the production of fertility hormones, being sup-

plied either as API or finished injectables, in co-operation with an also GMP approved German license manufacturer. Our main products are: – Human Chorionic Gonadotrophin (HCG), – Human Menopausal Gonadotrophin (HMG), – Follicle Stimulating Hormone (FSH), – Urokinase (UK), Streptokinase and Ulinastatin (UTI). BSV BioScience GmbH is focused on different R&D activities, continuously pursuing improvements in the field of API´s and finished dosage forms.

Name bitop AG

Address Stockumer Str. 28 Postal Code/City 58453 Witten Fon Fax E-Mail Internet

+49 2302 914-400 +49 2302 914-4010 behne@bitop.de www.bitop.de

Founded (year) 1993

Name BSV Bioscience GmbH Address Max-Planck-Strasse 12 Postal Code/City 52499 Baesweiler Fon Fax E-Mail Internet

+49 2401 8047-10 +49 2401 8047-198 office@bsvbio.de www.bsvbio.de

Employees 18 Founded (year) 2007

BIO.NRW

industrial biotechnology

Name Cysal GmbH Address Mendelstraße 11 Postal Code/City 48149 Münster Fon Fax E-Mail Internet

+49 251 980-2490 +49 251 980-2499 info@cysal.de www.cysal.de

Employees 5 Founded (year) 2012

The innovative biotechnology company Cysal GmbH was founded as a spin-out of the University of Münster, Germany. Cysal focuses on the production of novel biomaterials in the area of biopolymers, peptides, amino acids, and dipeptides on an industrial scale at unprecedented lowcost, and also develops application fields

supporting the needs of our customers and partners for sustainable and profitable processes which are urgently required by the developing BioEconomy.

Name Direvo Industrial Biotechnology GmbH Address Nattermannallee 1 Postal Code/City 50829 Köln Fon Fax E-Mail Internet

+49 221 47448-0 +49 221 47448-111 info@direvo.com www.direvo.com

Employees 30 Founded (year) 2008

At Direvo, we focus on the emerging biomass conversion industry. We are developing and marketing biology-based products and processes utilizing safe and sustainable resources for a world still dominated by fossil raw materials. Our powerful scientific tools unleash the full value of biomass in current and novel industrial processes. Direvo is committed to deliver the best technologies

Name evoxx technologies GmbH Address Alfred-Nobel-Str. 10 Postal Code/City 40789 Monheim am Rhein Fon Fax E-Mail Internet

+49 2173 4099-40 +49 2173 4099-440 contact@evoxx.com www.evoxx.com

Employees 40 Founded (year) 2016 (evocatal 2006)

for these biomaterials to serve humans and animals. Cysal’s business strategy aims at out-licensing its technology platform to interested companies and/or offering its raw materials for incorporation into consumer products for various markets. The main target markets are those for energy food additives and sport nutrition, cosmetics and skin care, dental hygiene, clinical nutrition, immunomodulation, impotence and infertility, as well as in the area of animal feed production, especially for aquaculture.

evoxx technologies GmbH, a German Industrial Biotechnology Company, is focusing on the development and production of industrial enzymes and novel carbohydrate ingredients produced by enzymatic bioconversion. With its proprietary enzymes and carbohydrate ingredients, evoxx is active in high growth markets addressing consumer needs in the Global Food Health

& Wellness Sector and Consumer Products Markets. Product development is based on the proprietary technology and patent platform covering the whole value chain from early enzyme and process development to industrial scale production and product deregulation. evoxx industrial partners and customers benefit from the unique metagenomics libraries, the enzyme and carbohydrate development skills and tech-transfer and production capabilities. evoxx is located on the Creative Campus in Monheim am Rhein and on the Biotech Campus Hermannswerder in Potsdam.

BIO.NRW

GEN-IAL GmbH is a specialist laboratory for DNA based food and feed analyses. GEN-IAL offers services and kits for GMO-, allergene- and animal identity analyses as well as bacteria- and yeast detection and differentiation. We offer training in PCR, contract research, several kits for DNAextraction, PCR-kits for beer/wine spoilage

industrial biotechnology

bacteria and yeast, pathogenes (Salmonella, Listeria, Campylobacter, Legionella), genetically modified organism (GMO), allergenes, plant and animal-identity. The laboratory is accredited (DIN EN ISO/IEC 17025) and official cross checking laboratory. We are member in the German official working group for method development for GMO detection and quantification. We are listed laboratory for the American NONGMO- Project. New: Capturing of microorganism by polymer technology

natural product based novel taste modulators. IMAX discovery is a 50:50 joint venture company between Axxam SpA in Milano, Italy, and IMD Natural Solutions GmbH in Dortmund, Germany. IMAX Discovery is a research driven company, creating new product innovation through the generation and development of novel and natural flavour compounds for the food and beverage industry. Using our strong technology platforms and expertise around taste receptors and natural products IMAX Discovery generates proprietary product pipelines of

IMD Natural Solutions (“INS”) aims to develop and commercialize groundbreaking ingredients – with a special focus on preserving and anti-microbial agents – derived from “all” natural sources. The main target markets are in the Food & Beverage as well as the Personal Care industries. Two product candidates are in advanced

Name GEN-IAL GmbH Address Heuserweg 13-15 Postal Code/City 53842 Troisdorf Fon Fax E-Mail Internet

+49 2241 252-2980 +49 2241 252-2989 info@gen-ial.de www.gen-ial.de

Employees 10 Founded (year) 1998

Name IMAX Discovery GmbH

Address Otto-Hahn-Str. 15 Postal Code/City 44227 Dortmund Fon Fax E-Mail Internet

+49 231 97427-402 +49 231 97427-401 info@imax-discovery.com www.imax-discovery.com

Founded (year) 2010

development: AM-1 represents a new (patent pending) all natural antimicrobial preserving agent well suited to support product specifications for food, beverage and personal care applications. AX-1 is targeting oil preservation via its strong antioxidant profile. INS follows a dual business model; besides the development of preserving agents INS provides Natural Product Service as one-stop service partner for all needs associated with Natural Product research, development, production or supply.

Name IMD Natural Solutions GmbH Address Postal Code/City Fon Fax E-Mail

Otto-Hahn-Str. 15 44227 Dortmund +49 231 9742-7400 +49 231 9742-7401 info@imd-naturalsolutions.com Internet www.imd-naturalsolutions.com Employees 10 Founded (year) 2012

BIO.NRW

industrial biotechnology

m2p-labs is a supplier of microbioreactors for the Life-Science industry. The company focuses on microreaction and automated solutions for screening and bioprocess development. The product portfolio comprises the BioLector®, the RoboLector® (automa-

tion) and the disposable FlowerPlate® (MTP) which provide an intelligent micro fermentation platform. This technology empowers the biotechnology, chemical and pharmaceutical industry to increase the number and the information content of microbial experiments (aerobic, microaerophilic and strict anaerobic). Experiments can be conducted with high efficiency and good quality at low costs. Automated fermentation of the whole bioprocess is possible with the RoboLector®, a combination of the BioLector® system with a standard liquid handling robot. m2p-labs | The Microbioreactor Company

multiBIND develops innovative decontamination, disinfection and hygiene solutions for molecular biology, healthcare and agriculture. Core technologies are patent-pending systems to generate new disinfection and decontamination agents for consumer markets, hospitals, laboratories and agro-

chemistry. bioDECONT® and bioCLEANTM are the only agents that in addition to the effective killing of microorganisms also accomplish safe and complete decontamination of genetic material (DNA/RNA). Besides the highly efficient antimicrobial action and decontamination properties they are nontoxic for humans, non-corrosive and free of organic solvents or other hazardous chemicals. multiBIND pursues a partnering strategy for new applications and markets from suitable industry sectors. multiBIND offers and holds multiple licenses for products and applications.

Name m2p-labs GmbH Address Arnold-Sommerfeld-Ring 2 Postal Code/City 52499 Baesweiler Fon Fax E-Mail Internet

+49 2401 805-330 +49 2401 805-333 info@m2p-labs.com www.m2p-labs.com

Employees 31 Founded (year) 2005

Name multiBIND biotec GmbH Address Gottfried-Hagen-Str. 60-62 Postal Code/City 51105 Köln Fon Fax E-Mail Internet

+49 221 2780-211 +49 221 2780-213 info@multibind.de www.multibind.de

Employees 3 Founded (year) 2005

is on the development of intelligent mixtures of hydrolases, to be used in a most efficient degradation of plant material, e.g. in the course of methane production from biomass.

Name Senzyme GmbH Address Gierlichsstr. 6 Postal Code/City 53840 Troisdorf Fon Fax E-Mail Internet

+49 2241 9715-2000 +49 2241 9715-2499 info@senzyme.de www.senzyme.de

Employees 30 Founded (year) 2000

Senzyme GmbH develops and produces technical enzymes and other microbiological products, all of which is well grounded in the company’s substantial experience in solid-state fermentation using filamentous fungi. Currently, the focus

BIO.NRW

For companies using enzymes in their processes or as additives in their products, SeSaM-Biotech is the right partner to boost the enzyme’s performance. With a combined approach of patented mutagenesis technologies and rational design by computational

W42 GmbH is your partner for enzyme production and process development. We offer: High performance heterologous protein production in Pichia sp. Wide range of different strains and promoters – best choice for your project. Methanol dependent and Methanol independent high yield protein production. Complete processes are offered including: strain

industrial biotechnology

modelling and simulations, SeSaM-Biotech tunes enzyme properties like activity, thermal resilience, protease resistance, solvent/ pH stability, and substrate/product inhibition. The track record includes proteases, monooxygenases, lipases, cellulases, amylases, phytases, esterases, glucose oxidases, pectinases, isomerases, laccases, and xylanases being applied in the biotechnological sectors pharma, chemistry, cosmetics, flavors, nutrients, feed, laundry, food/beverages, biofuel, textiles and paper. All protein evolution projects are provided as a service with attractive IP ownership agreements.

development – fermentation – DSP – enzyme immobilisation. Since 2005 W42 GmbH has carried out many successful projects for industrial partners in Europe and P.R. China. Several improved strains are running on industrial scale for production of technical enzymes. Furthermore W42 is working on rational strain improvement of microorganisms for the optimisation of industrial production of natural compunds (e.g. antibiotics).

Name SeSaM-Biotech GmbH

Address Forckenbeckstraße 50 Postal Code/City 52074 Aachen Fon +49 241 93856979 E-Mail info@sesam-biotech.com Internet www.sesam-biotech.com Founded (year) 2008

Name W42 Industrial Biotechnology GmbH Address Otto-Hahn-Straße 15 Postal Code/City 44227 Dortmund Fon +49 231 94178991 E-Mail info1@w42biotechnology.de Internet www.w42biotechnology.de Employees 3 Founded (year) 2005

BIO.NRW

Agrobiotechnology 58

BIO.NRW

It is estimated that plant pathogens are responsible of world-wide losses in the range of billions of Euros per year. Therefore, there is a strong need to provide effective, broad range and environmentally friendly approaches to ensure protection of plants

Deutsche Saatveredelung AG is an international plant breeding company with headquarters in Germany. The main focus is on research and development in breeding and seed production for different crop plant species. Our major products include rapeseed, wheat, barley, corn/maize, pasture and

The company MykoMax was created in October 1999 in the legal form of a limited company (GmbH). The enterprise article of the society is the study, development and production of biotechnology products on the basis of fungi. The company offers al-

agrobiotechnology

from pathogens. We developed a patented platform based on antibody fusions which ensures plant protection from fungal and bacterial infections. This alternative approach for controlling plant pathogens and parasites aims at minimising the costs for cultivation of crops thereby reducing the toxic effects of pesticides and toxins for human beings. AgroProtect GmbH licences its proprietary technology and offers the generation of pathogen resistant plants as well as access to novel resistant cultivars of several crops.

turf grasses, and different intercrop species. Breeding is run on nine breeding stations in Europe and two in Canada. We are dedicated to our purpose: Innovation for your growth. Seed of new varieties is produced and processed mostly in Europe and sold world-wide. In the framework of several cooperations in breeding, production, marketing and sales DSV is partner of several competitive enterprises on the national and international level.

ready within the mycological product range several self-developed mycorrhiza-inoculi. On short and medium-term the company MykoMax GmbH would development new drugs from medicinal effective mushrooms for the pharmaceutical use. Thereby the company uses a self-developed method for the extraction of the active ingredients in the mushrooms.

Name AgroProtect GmbH

Address ForckenbeckstraĂ&#x;e 6 Postal Code/City 52074 Aachen Fon Fax E-Mail Internet

+49 2451 9148783 +49 2451 9148784 info@agroprotect.de www.agroprotect.de

Founded (year) 2010

Name Deutsche Saatveredelung AG Address Weissenburger StraĂ&#x;e 5 Postal Code/City 59557 Lippstadt Fon Fax E-Mail Internet

+49 2941 296-0 +49 2941 296-100 info@dsv-saaten.de www.dsv-saaten.de

Employees 600 Founded (year) 1923

Name MykoMax GmbH Address Flieth 39 Postal Code/City 42327 Wuppertal Fon Fax E-Mail Internet

+49 202 3171-320 +49 202 3171-3210 info@mykomax.de www.mykomax.de

Employees 3 Founded (year) 1999

BIO.NRW

agrobiotechnology

Name Phytowelt GreenTechnologies GmbH Address Kölsumer Weg 33 Postal Code/City 41334 Nettetal Fon Fax E-Mail Internet

+49 2162 77859 +49 2162 89215 contact@phytowelt.com www.phytowelt.com

Employees 30 Founded (year) 1998

Phytowelt operates industrial plant biotechnology. It is a leading provider for the identification and expression of genes encoding plant enzymes with new activities for industrial fermentation processes with a main activity on fatty acids, terpenoids and plant P450 enzymes. Additionally

Name Saaten-Union Biotec GmbH Address Hovedisser Str. 94 Postal Code/City 33818 Leopoldshöhe Fon +49 5208 9597-10 Fax +49 5208 9597-195 E-Mail info@saaten-unionbiotec.com Internet www.saaten-unionbiotec.de Employees 70 Founded (year) 1984

BIOTEC Saaten-Union Biotec offers services and contract research in the field of plant breeding (wheat, rapeseed, barley, triticale, oat, hybrid rye, durum wheat, fodder and amenity grasses). The development

Phytowelt offers solutions in plant breeding to improve plants by protoplast fusion and double haploid production Phytowelt’s improvement of biomass production by this accelerated breeding processes is the basis for the biorefinery concept to be realized in the coming years. The USP of a poplar breeding collection combined with the unique fermentation process for terpenes in E.coli, especially carotinoids is one of the success factors for Phytowelt. The raspberry flavour, R-Alpha-Ionone will be one of the first products fermentatively produced.

of new varieties of cereals, rapeseed and other crops is strongly build upon innovation. Application of tissue culture technologies (doubled haploids, embryo rescue) and molecular marker applications are routinely used in a wide range of crops and for a significant number of breeding traits.

BIO.NRW

agrobiotechnology

BIO.NRW

Bioinformatics 62

BIO.NRW

The Institut für Innovationstransfer GB Biotech (IIT Biotech) offers integrated genomic services. Since some years the main provided service is the ’next generation sequencing’.

The Ridom GmbH (Münster, Germany) was founded January 2003. The company develops software for DNA re-sequencing analysis for physicians and epidemiologists on routine basis. The company has in the meantime by its software products a well-recognized name in the field of sequence based microbial typing;

bioinformatics

The high-throughput techniques performed by Illumina HiSeq and MiSeq or by IonTorrent PGM can be offered combined with a powerful lab & bioinformatic pipeline providing full service tasks like genomic assembly, gap closure and annotation. Furthermore we offer individual solutions for the bioinformatic evaluation of project data. This includes construction of draftgenomics, storage/care of genome projects, analysis in resequencing and metagenomics and development/customization of analysissoftware.

e.g., every European National Health System Authority (e.g., RKI, RIVM, HPA, Serum Statens) has bought in the last 10 years and is using since then at least one software product from Ridom. Ridom has pioneered typing efforts with a software tool for Staphylococcus aureus. The company has developed and maintains the worldwide largest sequencebased microbial typing database (Ridom SpaServer). The SPA typing software Ridom StaphType is currently used by approximately 400 users in 36 different countries worldwide. The new Ridom SeqSphere+ software provides a bacterial typing solution for any bacteria, any study type, any lab.

Name IIT BioTech - Institut für Innovationstransfer an der Universität Bielefeld GmbH Address Universitätsstr. 25 University of Bielefeld Postal Code/City 33615 Bielefeld Fon +49 521 100-775 Fax +49 521 102-313 E-Mail service@iit-biotech.de Internet www.iit-biotech.de Employees 9 Founded (year) 1995

Name Ridom GmbH

Address Mendelstr. 11 Postal Code/City 48149 Münster Fon Fax E-Mail Internet

+49 251 490931-50 +49 251 490931-51 info@ridom.de www.ridom.de

Employees 4 Founded (year) 2003

BIO.NRW

Other Biotechnologically Active Companies 64

BIO.NRW

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its inno-

German Seed Alliance GmbH is an alliance of four leading German plant breeding companies in international agriculture: Deutsche Saatveredelung, Norddeutsche Pflanzenzucht, Nordsaat Saatzucht and SaKa. The company and its shareholders are internationally experienced enterprises in the field of plant research and development, breeding, seed production and distribution.

other

the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the hightech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.

Name Bayer AG

Address Kaiser-Wilhelm-Allee Postal Code/City 51368 Leverkusen Fon +49 214-30-1 Internet www.bayer.com Employees 117,000

For more information, go to www.bayer.com

vative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,000 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.4 billion. Evonik innovates and serves the bioeconomy markets. Products are i. a. Biolys®, DYNACOLL ® Terra, DYNAPOL ® Terra, RESOMER®, ThreAMINO ®, TrypAMINO ®, and VESTAMID ® Terra.

The main focus is on oilseed rape, potatoes, corn, sunflower, grasses, peas and cereals (especially wheat, barley, rye, oat and triticale). German Seed Alliance coordinates all research programs of the group and is partner of the national and international scientific community in plant research and biotechnology. New varieties are developed and high quality seeds are produced for different climate regions. In sales the first focus is on Russian Federation, with innovative solutions and wide range of seed products combined with professional service and individual consultancy.

Name Evonik Industries AG Address Rellinghauser Str. 1-11 Postal Code/City 45128 Essen Fon Fax E-Mail Internet

+49 201 177 01 +49 201 177 3475 bioeconomy@evonik.com www.evonik.com

Employees 33,000 Founded (year) 2007

Name German Seed Alliance GmbH Address Erdmund-Rumpler-Straße 6 Postal Code/City 51149 Köln Fon Fax E-Mail Internet

+49 2203 9888-20 +49 2203 9888-229 info@german-seed-alliance.de www.german-seed-alliance.de

Employees 45 Founded (year) 2008

BIO.NRW

other

Name Grünenthal GmbH

Address Zieglerstr. 6 Postal Code/City 52099 Aachen Fon +49 241 569-0 E-Mail info@grunenthal.com Internet www.grunenthal.com Employees 5,400 Founded (year) 1946

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innova-

Name Henkel AG & Co. KGaA Address Postal Code/City Henkelstr. 67 40191 Düsseldorf Fon Fax +49 211 7979630 E-Mail +49 211 7982245 Internet www.henkel.com Employees 49,000 Founded (year) 1876

Henkel operates worldwide with leading brands and technologies in three business areas: Laundry & Home Care, Beauty Care and Adhesive Technologies. Founded in 1876, Henkel holds globally leading market positions both in the consumer and industrial businesses with wellknown brands such as Persil, Schwarzkopf and Loctite.

Name Janssen-Cilag GmbH Address Johnson & Johnson Platz 1 Postal Code/City 41470 Neuss Fon +49 2137 9550 Fax +49 2137 955599 Internet www.janssen-deutschland.de Employees 800 (Germany), 40,000 (worldwide) Founded (year) 1959

Janssen-Cilag is a research-based pharmaceutical company that develops and markets pharmaceutical products and services. The Janssen Pharmaceutical Companies of Johnson & Johnson with worldwide 40,000 employees develop innovative medicines for the treatment of severe chronic conditions

tion in order to treat unmet medical needs and bring valueadding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-theart technologies to patients. Altogether, the Grünenthal Group is present in 32 countries with affiliates in Europe, Latin America and the US. Grünenthal products are sold in more than 155 countries and approx. 5,400 employees are working for the Grünenthal Group worldwide. In 2015, Grünenthal achieved revenues of € 1.2 bn.

Henkel employs about 49,000 people and reported sales of 18,089 million euros and adjusted operating profit of 2,923 million euros in fiscal 2015. Henkel’s preferred shares are listed in the German stock index DAX.

and evaluates programmes that improve therapies beyond the mere administration of drugs. Janssen is dedicated to addressing and solving the most important unmet medical needs of our time, including oncology, immunology, neuroscience and infectious diseases. Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency. More information can be found at www.janssen-emea.com and www.janssendeutschland.de

BIO.NRW

other

conserving more of our world’s natural resources such as water and energy.

Name Monsanto Agrar Deutschland GmbH Address Vogelsanger Weg 91 Postal Code/City 40470 Düsseldorf

Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. Monsanto remains focused on enabling both small-holder and large-scale farmers to produce more from their land while

Since over 70 years, Pharma Waldhof GmbH, located in Düsseldorf/Germany, is active in the unique world of Nucleic Acid Biochemistry. The last milestones in our long company history were in 2014 and 2016 the award of the label “Innovative through Research” by the “Stifterverband für die deutsche Wissenschaft” and in 2015 the acknowledgement by the “Deutscher Bildungspreis” as

Syngenta is one of the world’s leading companies in agribusiness with more than 26,000 employees in over 90 countries. We are dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve

Fon Fax E-Mail Internet

+49 211 3675-0 +49 211 3675-362 mon@monsanto.de www.monsanto.de

Founded (year) 2000

an “Excellence company for Training and Talent Management”. Development of new products using cutting-edge technology enables us to apply our high standards and quality values into innovative, powerful and well-accepted products designed for existing and new markets. Our success is based on our highly skilled people and pursuit for delivering quality value added products serving the worldwide market in various segments like Pharma APIs and Intermediates; Cosmetics; Nutrition and Diagnostics. Pharma Waldhof belongs to the multi-national Aceto Group/USA.

health and quality of life. At the core of our business is innovation, particularly in research and development, combining chemical and biological expertise. We harness our knowledge of agriculture and our understanding of growers to develop integrated offers which will drive land productivity in a sustainable way.

Name Pharma Waldhof GmbH Address Hansaallee 159 Postal Code/City 40549 Düsseldorf Fon Fax E-Mail Internet

+49 211 52602-43 +49 211 52602-22 info@pharmawaldhof.de www.pharmawaldhof.de

Employees 13 Founded (year) 1974

Name Syngenta Seeds GmbH Address Zum Knipkenbach 20 Postal Code/City 32107 Bad Salzuflen Fon +49-5222 5308-0 E-Mail internet.marketing@ syngenta.com Internet www.syngenta.de Employees 150 Founded (year) 2000

BIO.NRW

other

Name Taros Chemicals GmbH & Co. KG Address Emil-Figge-Str. 76 a Postal Code/City 44227 Dortmund Fon Fax E-Mail Internet

+49 231 9742-7211 +49 231 9742-7219 info@taros.de www.tarosdiscovery.com

Employees 55 Founded (year) 1999

Taros, a privately owned CRO / CMO has been serving the needs of pharmaceutical, chemical and biotech companies since 1999. More than 10.000 synthesis, research and process chemistry projects have successfully been delivered to the global customer base. Taros’ scientists combine more than 140 years industrial organic chemistry

Name UCB Pharma GmbH UCB Biosciences GmbH

Hovedisser Str. 92 33818 Leopoldshöhe +49 5208 9125-30 +49 5208 9125-49 info@wvb-eckendorf.de www.wvb-eckendorf.de

Employees 40 Founded (year) 1849

KEND

Address Postal Code/City Fon Fax E-Mail Internet

Name W. von Borries-Eckendorf GmbH & Co. KG Pflanzenzuchtbetrieb

ORTE

Founded (year) 1928 (Belgium)

+49 2173 4848-48 +49 2173 4848-41 ucbcares.de@ucb.com www.ucb.com; www.ucb.de

Fon Fax E-Mail Internet

UCB is a global biopharmaceutical company focusing on severe diseases in two therapeutic areas – CNS and immunology. UCB also has a selective presence in primary care. UCB is connecting science in new ways, notably chemistry and biology, so that they can leverage the potential of these two disciplines, as well as illuminate the

Address Alfred-Nobel-Str. 10 Postal Code/City 40789 Monheim

RFER

W. von Borries-Eckendorf is a medium-sized family-owned company, founded in 1849 by Wilhelm von Borries (1805-1890), a prominent farmer and talented plant breeder. Starting with the “Eckendorfer” fodder beet,

experience and over 60 years of active drug discovery experience. They have expertise in major therapeutic areas and in all small molecule target classes. Taros have developed TarosGate ® , a unique software suite putting cost, time and chemistry information at a Project Leader’s finger tips - 24h/7 from anywhere in the world. TarosGate® is a major cornerstone of the 200 Mio. Euro European Lead Factory drug discovery platform.

biological pathways involved in severe diseases. The complexities of severe diseases are beyond the expertise and resources of a single organisation. Developing and commercialising innovative therapies is often the result of strong partnerships. That is why we value partnering with leading academic, biotech and pharma companies to bring new solutions for patients. There is no such thing as an “average patient”. We are seeking to embed the real needs of specific patient populations in our science and innovation process.

WvB is nowadays well known for strong breeding programs in oilseed rape, barley and high yielding wheat varieties. The company based in Lippe is founding member of the Rapool Ring GmbH and the Saaten-Union Biotec GmbH. Along with other breeding companies, Eckendorf is significantly involved in one of the largest distributors in the German sector of seed. The Saaten-Union GmbH.

BIO.NRW

other

bio.nrw.de company database

Innovative biotech companies in North Rhine-Westphalia. BIO.NRW offers free of charge a well-organized and comprehensive database of life science and biotech companies resident in North RhineWestphalia. The database currently includes 450 company profiles, contact details and a summary of products, services and technologies and is updated frequently several times per year. phone: +49 211 38 54 69-9200 â&#x20AC;˘ E-Mail: bio.nrw@bio.nrw.de

BIO.NRW

BIO.NRW Cluster Biotechnology North Rhine-Westphalia North Rhine-Westphalia is situated at Europe’s geographic and economic center. It is the largest of Germany’s 16 federal states, and the number one exporter. If classified as an independent exporting nation, NRW would rank 19th in the world, on a par with the Netherlands. North Rhine-Westphalia’s state government has established a number of technology clusters to systematically improve NRW’s strengths and talents in established industries and up-and-coming fields like biotechnology. North Rhine-Westphalia’s biotechnology cluster BIO.NRW is a central catalyst for the sustainable development of the state’s biotech sector. It activates cooperation between business, research, investors and policy-makers. The cluster also promotes the strengths and achievements of biotechnology in the state. To support young as well as already established biotech companies, BIO.NRW offers the following core competencies: – Individual matchmaking for collaborations and partners – Overview on all up-to-date R&D activities in industry and academia – Profound knowledge on financing possibilities – International promotion and marketing for NRW as biotech location – Direct contacts to decision makers

dialogue between all stakeholders in the field of biotechnology and to encourage cooperation.

Biotech Business & Sciences BIO.NRW compiles comprehensive and current online databases of the academic institutions and companies active in the life sciences in NRW. Free to access and easyto-use, these resources are valuable tools for identifying prospective business partners. More information on www.bio.nrw.de

Fairs, Exhibitions and Conferences Companies and academic institutions can generate awareness of their activities locally, nationally and internationally by being a part of the BIO.NRW common stands on fairs, exhibitions and conferences. BIO.NRW also organizes a series of workshops and symposia, called BIO.NRW.academy.

Support of Young Professionals

Technology Transfer

BIO.NRW takes a special interest in supporting young professionals in biotechnology. For example, we organize conventions where graduates meet representatives from industry and academic science. The ‘Business Angel Network – BIO.NRW’ helps financing and funding biotech start-ups. In addition, a forum that brings together investment institutions, private investors and business angels and developers provides information about the current NRW biotech scene. These meetings are a valuable opportunity for start-up companies to receive coaching and financing.

Tech transfer support is a key contribution from BIO.NRW. We organize events, working platforms and meetings to promote the

To learn more about the Cluster BIO.NRW and to stay informed about the latest

Our services include

biotech developments in NRW please visit www.bio.nrw.de. Further drivers in the field are dynamic local biotechnology initiatives and networks: Bioanalytik-Münster www.bioanalytik-muenster.de BioCologne www.biocologne.de bio.dortmund www.wirtschaftsfoerderung-dortmund.de BioIndustry www.bioindustry.de BioRiver www.bioriver.de Bio-Tech-Region OWL www.bio-owl.de LifeScienceNet Düsseldorf www.lifescience-dus.de MedLife (Aachen) www.medlife-ev.de Cluster Industrial Biotechnology www.CLIB2021.com

Denmark

BIO.NRW

Kiel Hamburg

Netherland

Bremen

Schwerin

Poland

Berlin Magdeburg Hannover

Potsdam

Düsseldorf

Belgium

Erfurt

Dresden

Frankfurt

Luxembourg

Czech Republic

Mainz

Saarbrücken

France

Stuttgart München

Austria Switzerland

BIO.NRW

Glossary

Organisation for Economic Co-operation and Development (OECD) The OECD is a unique forum where the governments of 30 democracies work together to address the economic, social and environmental challenges of globalisation. The OECD Biotechnology Statistics, which brings together the latest available economic and activity data on biotechnology and innovation, is collected by OECD member and non-member countries. The report builds on the extensive work of the OECD and national experts to improve the comparability of biotechnology statistics. www.oecd.org

OECD Definitions

Other biotechnologically active companies … firms that apply biotechnology techniques for the purpose of implementing new or significantly improved products or processes. This definition excludes end users that innovate simply by using biotechnology products as intermediate inputs (for instance, detergent manufacturers that change a formulation to include enzymes produced by other firms via biotechnology techniques).

Business Areas of Activity – Health/Medicine (including animal health) Development of therapeutics and/or diagnostics for the field of human medicine, drug delivery, human tissue replacement.

– Agri/Agrobiotechnology Biotechnology company … is defined as a application of science and technology to living organisms, as well as parts, products and models thereof, to alter living or non-living materials for the production of knowledge, goods and services.

Dedicated biotechnology companies … are defined as biotechnology active firms whose predominant activities involve the application of biotechnology techniques to produce goods or services and/or the performance of biotechnology R&D. 72

Biotech focussed on genetically modified plants, animals or microorganisms, as well as non-genetically modified plants grown using biotechnological procedures for use in agriculture or forestry.

– Industrial biotechnology Biotechnological products and processes for the handling of waste or sewage, for chemical synthesis, for the extraction of raw materials and energy, etc.

– Non-specific application Equipment or reagents based on biotechnological principles for research or provision of services in this field (“ancillary industry”). Source: biotechnologie.de

Contact BIO.NRW Dr. Christoph Block Head of office BIO.NRW Merowingerplatz 1 40225 Düsseldorf, Germany Fon +49 211 385469-9202 Fax +49 211 385469-9220 ch.block@bio.nrw.de www.bio.nrw.de

Sources, Literature, Links [1] www.nrwinvest.com/en/nrw-at-a-glance/ location-factors-nrw/business-locationgermany-nrw/ [2] World Bank 07/2016 [3] Analysis by BIO.NRW and BIO Deutschland e.V. [4] Estimating the biotech sector’s contribution to the US economy; Robert Carlson; Nature Biotechnology 34, 247–255 (2016) [5] OECD Biotechnology Statistics 2009, B. van Beuzekom and A. Arundel [6] NRW PCT Biotech Patent Analysis by BIO.NRW [7] statista [8] Compared to surveys from Biocom 14/15 [9] http://data.worldbank.org/indicator/ GB.XPD.RSDV.GD.ZS [10] statista - Leading German dedicated biotechnology companies by number of employees worldwide in 2015 [11] www.biotechgate.com; Venture Valuation, Zurich, CH [12] Based on own survey in comparison to: Im Schatten von Leuchttürmen, Potenziale besser ausschöpfen, Deutscher Biotechnologie-Report 2016, Ernst & Young GmbH [13] Biotech-Report “Medizinische Biotechnologie in Deutschland 2016” von vfa bio und BCG; www.vfa-bio.de [14] www.leitmarktagentur.nrw/leitmarktwettbewerbe/lifesciences/runde1

BIO.NRW

Apply Now

Welcome to our private equity community Apply for funding from business angels and investors! Register and upload your 3-minute biotech/life science company video! Get the attention of a large investors community and get invited to a face-to-face meeting! What are you waiting for?

www.startups4.eu

BIO Clustermanagement NRW GmbH Merowingerplatz 1 40225 DĂźsseldorf, Germany

phone: +49 (0) 211 942 150 49 mail: info@bioclustermanagement.de web: www.bioclustermanagement.de 73

BIO.NRW

Onli

pany m o C base a t a D de nrw. . o i b . www

BIO.NRW Merowingerplatz Merowingerplatz 11 40225 40225 Duesseldorf Düsseldorf, Germany Germany Fon +49 211 385469-9200 Fon + 49 (0) 2 11 385 469 - 9200 Fax +49 211 385469-9220 Fax + 49 (0) 2 11 385 469 - 9220 bio.nrw@bio.nrw.de bio.nrw@bio.nrw.de www.bio.nrw.de www.bio.nrw.de Ministry of Innovation, Innovation, Science Science, Research and Technology of the and Research of the German State State of North Rhine-Westphalia of North Rhine-Westphalia 40221 40221 Duesseldorf Düsseldorf www.innovation.nrw.de www.innovation.nrw.de www.exzellenz.nrw.de ‘Excellence NRW’ stands for the cluster strategy in North Rhine-Westphalia, an innovative location for business. The state government there wants to improve on its strengths, and systematically strive for excellence in NRW. The goal of the cluster policy is to create an environment that is friendly to innovation, strengthens the competitive edge of the businesses there, and stimulates growth and employment. To find out more about NRW’s cluster strategy and the 16 clusters in the state, just visit: www.exzellenz.nrw.de